CURRICULUM VITAE
University of Colorado, Denver
Barbara Davis Center
1775 Aurora Ct., Box F-528, M20
Aurora, CO 80045
Ronald G. Gill, PhD
US Citizen
Married / 4 children
Phone 303.724.5321
Fax 303.724.7624
E-mail ronald.gill@ucdenver.edu
EDUCATION
1977/11-1985/02
PhD
Biology
University of California, Los Angeles
Thesis: The effect of exogenous fatty acids on cellmediated cytolysis (Supervisor: Dr. W.R. Clark)
1972/09-1976/08
BA
Biology
University of California, Los Angeles
PROFESSIONAL APPOINTMENTS
2009/11-present
2002/11-present
2009/01-2009/10
2007/04-2009/10
2007/04-2009/10
2007/04-2009/10
2002/03-2007/03
2001/07-2007/03
1996/09-2007/03
1992/10-2007/03
1996/08-2002/02
1993/06-1996/10
Updated: January 16, 2011
Scientific Director, Colorado Center for Transplantation Care, Research and
Education (CCTCARE)
Professor of Surgery and Immunology, University of Colorado, Denver
Adjunct Professor, Department of Surgery, U of Alberta, Canada
Scientific Director, Alberta Diabetes Institute, U of Alberta, Canada
Dr. Charles A. Allard Chair in Diabetes Research, Alberta Diabetes Institute,
U of Alberta, Canada
Professor, Department of Medical Microbiology and Immunology, U of Alberta,
Canada
Professor, Department of Medicine and Department of Immunology, U of
Colorado Health Sciences Center
Director, Rocky Mountain Islet Transplantation Program, NCRR Islet Cell
Resources Program
Director, Transplant Immunology Program, U of Colorado Health Sciences
Center
Member, Barbara Davis Center for Childhood Diabetes, U of Colorado Health
Sciences Center
Associate Professor, Department of Immunology, U of Colorado Health
Sciences Center
Acting Research Director, Barbara Davis Center for Childhood Diabetes, U of
Colorado Health Sciences Center
Page 1
Ronald G. GILL
1994/10-1996/07
1989/06-1994/09
1989/10-1992/09
1989/09-1991/08
1984/09-1989/08
1982/09-1984/08
1980/09-1982/08
Page 2
Assistant Professor, Department of Immunology, U of Colorado Health
Sciences Center
Assistant Professor, Department of Microbiology and Immunology, U of
Colorado Health Sciences Center
Associate Member, Barbara Davis Center for Childhood Diabetes, U of
Colorado Health Sciences Center
Instructor, Department of Microbiology and Immunology, U of Colorado
Health Sciences Center
Postdoctoral Fellow, Barbara Davis Center for Childhood Diabetes, U of
Colorado Health Sciences Center (Supervisor: Dr. K. Lafferty)
Teaching Fellow, Department of Biology, U of California, Los Angeles
Teaching Assistant, Department of Biology, U of California, Los Angeles
HONORS / AWARDS
2008/07-2015/06
2008
2004
2000
1991/07-1994/06
1990
1988
1988-1990
1986-1988
Scientist Award, Alberta Heritage Foundation for Medical Research
Mary Jane Kugel Award, JDRF Medical Science Review Committee
Mary Jane Kugel Award, JDRF Medical Science Review Committee
Chancellors Award for Teaching Excellence, Graduate School, U of Colorado
Health Sciences Center
Career Development Award (#291292), Juvenile Diabetes Foundation
Travel Award, The Transplantation Society
Travel Award, The Transplantation Society
Fellowship Award (#388180), Juvenile Diabetes Foundation
NIH Traineeship Award (#5 T32 AI-07035)
DEPARTMENTAL / UNIVERSITY COMMITTEES
2009/01-2009/10
2008/10-2009/10
2008/02-2009/10
2007/09-2009/10
2007/04-2009/10
External Member, Research Committee, Department of Medicine, U of Alberta
Member, Security Task Force Committee, Faculty of Medicine & Dentistry, U of
Alberta
Executive Committee Member, Faculty Animal Utilization Committee, Faculty
of Medicine & Dentistry, U of Alberta
Member, Muttart Diabetes Research & Training Centre, U of Alberta
Alberta Diabetes Institute, Faculty of Medicine and Dentistry, U of Alberta
o
o
2007/09-2008/08
2008/05
2000/06-2007/03
2006/01-2007/02
1999/09-2007/03
1999/09-2007/03
Chair – ADI Research Coordinating Committee (2007/04-present)
Chair – ADI Annual Research Day Organizing Committee (2007/04-present)
Member – ADI Board of Directors (2007/04-present)
o
Member, Search and Selection Committee, Medical Microbiology and
Immunology, U of Alberta
Podium Judge, Tom Williams Surgical Research Day, U of Alberta
(May 9, 2008)
Chair, Animal Resource Advisory Committee, U of Colorado Health Sciences
Center
Faculty Search Committee, Department of Surgery, U of Colorado Health
Sciences Center
Faculty Search Committee, Department of Immunology, U of Colorado Health
Sciences Center
Faculty Search Committee, Barbara Davis Center for Childhood Diabetes, U of
Colorado Health Sciences Center
Updated: January 16, 2011
Ronald G. GILL
1997/02-2007/03
1994/09-2007/03
1995/09-2007/03
1994/09-1997/12
1994/09-1996/06
1997/04
1997 & 1998
1993
Page 3
Co-Director, Univ. of Colorado Association of Transplant Physicians and
Surgeons
Member, Animal Resource Advisory Committee, U of Colorado Health
Sciences Center
Medical Scientist Training Program (MSTP) Faculty, U of Colorado Health
Sciences Center
Immunology Seminar Committee, U of Colorado Health Sciences Center
Transplantation Immunology Search Committee, U of Colorado Health Sciences
Center
Ad Hoc, HUI/SBR Grant Review Committee
Immunology graduate student recruiting lectures
Graduate School Recruiting (1997, 1998, 1999, 2000, 2001, 2002)
Member, Organizing Committee, Denver T Cell Symposium, U of Colorado
Health Sciences Center
NATIONAL AND INTERNATIONAL COMMITTEES
2009-present
2009-present
2009
2009-present
2010-present
2009/01-2013/12
2008/03-2009/10
2007/07-2009/10
2007/07-2009/10
2006/01-present
2008/04
2003/01-2007/12
1995-1998
Chair, Scientific Advisory Board, Juvenile Diabetes Research Foundation
Network for Pancreatic Organ Donors with Diabetes (nPOD)
External Evaluation Committee, NIDDK Integrated Islet Distribution Program
Chair, American Society of Transplantation, Basic Science Advisory Committee
DSMB member, NIDDK Clinical Islet Transplantation Consortium
Member, The Transplantation Society Basic Science Committee
Medical Review Panel, The Gairdner Foundation (Canada)
Board of Directors, Alberta Diabetes Foundation
Research Portfolio Advisory Committee (Immunology), Juvenile Diabetes
Research Foundation
Scientific Sessions Planning Committee, American Diabetes Association
Network Steering Committee, NIH Immune Tolerance Network
INVITED PARTICIPANT: Diabetes Policy Review Meeting, Government of
Canada, Calgary, Alberta (April 11, 2008)
Xenotransplantation Advisory Committee: National Institutes of Health
Councilor, Cell Transplant Society
GRANT REVIEWING
2008/06
2002-2006
2003-2004
1998/03-2003/02
2003
2002
2001
Chair, JDRF Review “Roles of Innate Immunity and Inflammation in Type 1
Diabetes” (New York, NY / June 4, 2008)
Steering Committee, NCRR Islet Cell Resources Center, Rocky Mountain Islet
Transplantation Program, U of Colorado Health Sciences Center
Research Executive Committee, Juvenile Diabetes Foundation International
Medical Advisory Committee, Alberta Foundation for Diabetes Research
Chair, Organizing Committee, Basic Sciences Symposium, International
Transplantation Society, Keystone, CO, 2003
Member, Organizing Committee, Denver Autoimmunity Workshop
Chair, Organizing Committee. 10th Anniversary Congress of the Cell Transplant
Society, Keystone, CO (October 14-17, 2001)
Updated: January 16, 2011
Ronald G. GILL
2000
1999
Page 4
Member, International Organizing Committee, Artificial Organs III, United
Engineering Foundation. Davos, Switzerland, 2000
Member, International Organizing Committee. International Pancreas and Islet
Transplant Society Congress. Sydney, Australia, 1999
JOURNAL EDITORIAL BOARDS
2005-present
1994-present
1995-present
1998-2000
Associate Editor, American Journal of Transplantation
Editorial Board, Transplantation
Editorial Board, Transplant Immunology
Editorial Board, Diabetes
JOURNAL REVIEWING
Scientific Manuscripts
o Regular Reviewer
 Journal of Immunology
o Ad Hoc Reviewer
 American Journal of Transplantation
 Blood
 Diabetes
 Diabetologia
 Journal of Autoimmunity
 Journal of Clinical Investigation
 Journal of Experimental Medicine
 Nature
 Nature Medicine
 Proceedings of the National Academy of Science (USA)
 Science
 Xenotransplantation
MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS
2001-present
1995-present
1993-present
1991-present
1991-present
1990-present
1989-present
1987-1995
American Society of Transplantation
Xenotransplantation Society
International Pancreas and Islet Transplantation Association
Cell Transplant Society – Founding Member
American Diabetes Association
American Association of Immunologists
The Transplantation Society
Professional Member, Juvenile Diabetes Foundation International
Grant and Abstract Review Committees - Chairs/Co-Chairs
Grant Reviewing
2006/08-2008/07
Chair, NIH/CSR “Transplantation, Tolerance, and Tumor Immunology Study
Section” (National Institutes of Health Center for Scientific Review)
Updated: January 16, 2011
Ronald G. GILL
2000-2002
2008/12
2005
2005
2004
1999/07
Abstract Reviewing
2008/09-2009/02
2007/09-2008/02
Page 5
Chair, NIH/CSR “Immunological Sciences Study Section” (National Institutes
of Health Center for Scientific Review)
Chair, JDRF Program Project Site Visit Member “Langer Evaluation”,
Cambridge, MA (December 17, 2008)
Chair, NIH Special Emphasis Review Panel, ZAI1 TH0I (MS) (Feb 17/05)
Chair, NIH Special Emphasis Review Panel, ZAI1 TH-1 (M2) (Feb 17/05)
Chair, NIH: Chair, Special Emphasis Review Panel, ZDK1 GRB-7 (M3)P (Apr
28/04)
Chair, JDFI Special Grant Site Visit Team, Chicago, IL
Co-Chair, Abstract Review Committee, 2009 American Transplant Congress
(Boston, MA, May 30-June 3, 2009)
Co-Chair, Abstract Review Committee, 2008 American Transplant Congress
(Toronto, ON, May 31-June 4, 2008)
Grant Review Committees and Ad hoc Reviewing
2003/08-2008/07
2005/07-2008/06
2001-2003
2010
2000-209
1995-present
2005
2004
2004
2002
2002
1997-2002
2001
2001
2000
2000, 2001
1999
1999
1997/03
1996/10
1996/06
1996/03
1995
1995
1995/02
1994
1994
Member, NIH/CSR “Transplantation, Tolerance, and Tumor Immunology Study
Section” (National Institutes of Health Center for Scientific Review)
Member, JDRF Medical Review Committee (Autoimmunity)
Member, JDRF Medical Review Committee
Ad hoc reviewer: NIH CSR SEP ZRG1 IMM-C program project review
Ad hoc: Canadian Diabetes Association grant reviewing
Alberta Heritage Foundation for Medical Research (ad hoc)
NIDDK: Islet Transplantation DSMB (Sept 19-20/05)
NIH: Special Emphasis Panel, ZRG1 ALY 02 (Apr 19/04)
NIH: Ad Hoc Reviewer, SAT Study Section (Feb 4/04)
NIH: Special Emphasis Panel ADK1 GRB 8 (01) (Aug 7/02)
NIH: Special Emphasis Panel ZG1 IMS (02) (Apr 19/02)
NIH/CSR Immunological Sciences Study Section
NASA/NIDDK/JDRF/NCRR : Advisor for RFA development for Islet
Encapsulation
JDFI: Ad Hoc Reviewer, Juvenile Diabetes Research Foundation
JDFI: Ad Hoc Reviewer, Juvenile Diabetes Foundation
Reviewer, Diabetes Endocrinology Research Center Pilot Program, Univ. Wash.
JDFI: Special Grant Site Visit Member, Seattle, WA
JDFI: Special Grant Site Visit Member, Harvard Medical School
Ad hoc review: American Diabetes Association grant review
Ad hoc review: NIH/NIDDK Surgery, Anesthesia, Trauma Study Section, Ad
Hoc reviewer (Oct 17-19/96)
Ad hoc review: NIH/NIAID Special Emphasis Panel (June 27/96)
Medical Research Council of Canada/JDFI Committee, Montreal, Canada
(March 25-26/96)
NIH: GCRC site visit member, Northwestern University
NIH: NIAID Special Emphasis Panel; RFA NIH-NIAID-95-05
NIH: NIDDK Surgery, Anesthesia, Trauma Study Section, Ad Hoc reviewer
(Feb 22-24/95)
NIH: NIDDK Surgery and Bioengineering Study Section, Ad Hoc reviewer
NIH: NIDDK Surgery, Anesthesia, Trauma Study Section, Ad Hoc reviewer
Updated: January 16, 2011
Ronald G. GILL
Updated: January 16, 2011
Page 6
Ronald G. GILL
Page 7
PUBLICATIONS
Peer-Reviewed Publications
1.
Clark W, Gill R. Effect of membrane lipid composition on immune cell function. In:
Twelfth International Leukocyte Culture Conference. M. Quastel, ed., Academic Press,
New York, pp. 613-619, 1979.
2.
Mandel G, Shimizu S, Gill R, Clark W. Alteration of the fatty acid composition of
membrane phospholipids in mouse lymphoid cells. J. Immunol. 120:1631-1636, 1978.
3.
Gill R, Clark W. Membrane structure-function relationships in cell-mediated cytolysis. I.
Effect of exogenously incorporated fatty acids on effector cell function in cell-mediated
cytolysis. J. Immunol. 125:689-695, 1980.
4.
Bialick R, Gill R, Berke G, Clark WR. Modulation of cell-mediated cytotoxicity function
after alteration of fatty acid composition in vitro. J. Immunol. 132:81-87, 1984.
5.
Lafferty KJ, Gill R, Babcock S. Tolerance induction in adult animals: the ciclosporin
anomaly. Prog. Allergy 38:247-257, 1986.
6.
Lafferty KJ, Babcock SK, Gill RG. Prevention of rejection by treatment of the graft: an
overview. In: Transplantation: progress and prospect (Meryman H, ed.), Alan R. Liss, Inc.
New York, pp. 87-117, 1986.
7.
Lafferty KJ, Gill R, Babcock S, Simeonovic C. Activation and expression of allograft
immunity. Prog. Transplantation 3:55-84, 1986.
8.
Babcock SK, Gill RG, Bellgrau D, Lafferty KJ. Studies on the two signal model for T cell
activation in vivo. Transplant Proc. 19:303-306, 1986
9.
Lafferty KJ, Gill RG, Babcock SK, Wang Y. Active and passive antigen presentation: its
role in the induction of tissue immunity and allograft tolerance. Prog. Immunol. 6:10401054, 1986.
10.
Lafferty KJ, Prowse SJ, Babcock SK, Gill RG. The allograft response. Surg. Clinics of N.
Amer. 66:1231-1253, 1986.
11.
Gill RG, Babcock SK, Lafferty KJ. A quantitative analysis of antigen-triggered lymphokine
production by activated T cells. J. Immunol. 138:1130-1136, 1987.
12.
Wang Y, Hao L, Gill RG, Lafferty KJ. Autoimmune diabetes in the NOD mouse is L3T4 Tlymphocyte dependent. Diabetes 36:535-538. 1987.
13.
Haug CE, Gill RG, Babcock SK, Lafferty KJ, Bellgrau D, Weil R, III. Cyclosporineinduced tolerance requires antigens capable of initiating an immune response. J. Immunol.
139:2947-2949, 1987.
14.
Hao L, Wang Y, Gill RG, Lafferty KJ. Role of the L3T4+ T cell in allograft rejection. J.
Immunol. 139:4022-4026, 1987.
15.
Hao L, Wang Y, Gill RG, Lafferty KJ. CD4 T cells and allograft rejection. Transplant.
Proc. 20:56-60, 1988
16.
Gill R, Lafferty KJ. A novel form of T-T collaboration requiring the active participation of
the antigen presenting cell. Ann. N.Y. Acad. Sci. 532:421-423, 1988.
17.
Gill RG, Wang Y, Lafferty KJ. Spontaneous tolerance induction in adult animals
transplanted with allogeneic islets. Transplant. Proc. 20:61-63, 1988.
Updated: January 16, 2011
Ronald G. GILL
Page 8
18.
Gill RG, Lafferty KJ. Regulation of lymphokine release involving a novel form of T-T
collaboration. Transplant. Proc. 21:2700-2702, 1989.
19.
Gill RG, Lafferty KJ. Role of islet transplantation in the treatment of insulin-dependent
diabetes mellitus. Imm. Allergy Clin. No. Amer. 9:165-186, 1989.
20.
Lafferty KJ, Gill RG. Current controversies and new horizons: is there a clinical future for
the modulation of donor organ immunogenicity? In: Organ transplantation: current clinical
and immunological concepts (Brent L and Sells RA, ed.), Bailliere Tindall, Ltd. London pp.
167-176, 1989.
21.
Gill RG, Rosenberg AS, Lafferty KJ, Singer A. Characterization of primary T cell subsets
mediating rejection of pancreatic islet grafts. J. Immunol. 143:2176-2178, 1989.
22.
Gill RG, Lafferty KJ. A quantitative analysis of lymphokine release from activated T cells:
evidence for a novel form of T-T collaboration in vitro. J. Immunol. 143:4009-4014, 1989.
23.
Gill RG, Lafferty KJ. Antigen, cytokines, and the regulation of the allograft response.
Prog. Immunol. 7:1163-1170, 1989.
24.
Hao L, Wang Y, Gill RG, LaRosa FG, Talmage DW, Lafferty KJ. Role of γ-interferon in
islet allograft rejection: class I MHC antigen induction. Transplant. Proc. 21:2697-2699,
1989.
25.
Gill RG, Lafferty KJ. The nature of T-T collaboration in the rejection of class I MHCdisparate pancreatic islet allografts. J. Cell. Biochem (Supp. 13A):1318, 1989.
26.
Hao L, Wang Y, Gill RG, LaRosa F, Talmage D, Lafferty KJ. Role of lymphokine in islet
allograft rejection. Transplantation 9:609-614, 1990.
27.
Gill RG. Role of passenger leukocytes in islet allograft immunity. Clinical Transplant.
4:176-180, 1990.
28.
Wang Y, Pontesilli O, Gill RG, LaRosa FG, Talmage DW, Lafferty KJ. The role of CD4+
and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc.
Natl. Acad. Sci. USA 88:527-531, 1991.
29.
Gill RG. Transforming growth factor beta prevents islet allograft rejection. Transplant.
Proc. 23:747-748, 1991.
30.
Coulombe M, Hao L, Calcinaro F, Gill RG, Eugui EM, Allison AC, Lafferty KJ. Tolerance
induction in adult animals: comparison of RS-61443 and anti-CD4 treatment. Transplant.
Proc. 23:(Suppl 2) 31, 1991.
31.
Hao L, Calcinaro F, Gill RG, Eugui EM, Allison AC, Lafferty KJ. Facilitation of specific
tolerance induction in adult mice by RS-61443. Transplantation 53:590-595, 1992.
32.
Gill RG. The role of direct and indirect antigen presentation in the response to islet
xenografts. Transplant. Proc. 24:642-643, 1992.
33.
Gill RG, Coulombe M. Rejection of pancreatic islet xenografts does not require CD8+ T
lymphocytes. Transplant. Proc. 24:2877-2878, 1992.
34.
Gill RG, Haskins K. Molecular mechanisms underlying diabetes and other autoimmune
disease. Immunol. Today 14:49-51, 1993.
35.
Gill RG, Hao L, Lafferty KJ. Antigen presentation and alloimmunity. In: Immunology of
Liver Transplantation (Neuberger J and Adams D, ed.), Edward Arnold, pp. 115-126, 1993.
36.
Wolf L, Gill RG. Xenoreactive T-cell lines initiate pancreatic islet graft destruction in vivo.
Transplant. Proc. 25:440-441, 1993.
Updated: January 16, 2011
Ronald G. GILL
Page 9
37.
Lafferty KJ, Gill RG. The maintenance of self tolerance. Immunol. Cell Bio. 71:209-214,
1993.
38.
Gill RG. Pancreatic islet xenotransplantation. Autoimmunity 15 (Suppl 1):18-20, 1993.
39.
Gill RG. T-cell-T-cell collaboration in allograft responses. Curr. Opinion Immunol.
5:782-787, 1993.
40.
Wegmann DR, Shehadeh N, Lafferty KJ, Norbury-Glaser N, Gill RG, Daniel D.
Establishment of islet-specific T-cell lines and clones from islet isografts placed in
spontaneously diabetic NOD mice. J. Autoimmunity 6:517-527, 1993.
41.
Shehadeh NN, Gill RG, Lafferty KJ. Mechanism of self-tolerance to endocrine tissue.
Springer Semin. Immunopathol. 14:203-220, 1993.
42.
Coulombe M, Gill RG. Tolerance induction to cultured islet allografts: I. characterization
of the tolerant state. Transplantation 57:1195-1200, 1994.
43.
Coulombe M, Gill RG. Tolerance induction to cultured islet allografts: II. status of
antidonor reactivity in tolerant animals. Transplantation 57:1201-1207, 1994.
44.
Leiter EH, Gill RG. Prevention of autoimmune diabetes in the BB rat by intrathymic islet
transplantation at birth. J. Endocrin. Invest. 17:595-599, 1994.
45.
Wegmann DR, Gill RG, Norbury-Glaser M, Schloot N, Daniel D. Analysis of the
spontaneous T cell response to insulin in NOD mice. J. Autoimmunity 7:833-843, 1994.
46.
Coulombe M, Lafferty KJ, Gill RG. Nature of tolerance induction to peripheral
(extrathymic) islet allografts. Transplant. Proc. 26:720-721, 1994.
47.
Gill RG, Coulombe M. Islet xenografting in autoimmune diabetes. Transplant. Proc.
26:1140-1141, 1994.
48.
Gill RG, Wolf L, Daniel D, Coulombe M. CD4+ T cells are necessary and sufficient for
islet xenograft rejection. Transplant. Proc 26:1203, 1994.
49.
Gill RG. 1994. Pancreatic islet transplantation. In: Molecular Biology of Diabetes, Part I
(Draznin B and LeRoith D, ed.), Humana Press Inc, Totowa, New Jersey pp 49-67, 1994.
50.
Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile
and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur. J.
Immunol. 25:1056-1062, 1995.
51.
Gill RG, Eisenbarth G. Juvenile diabetes foundation International workshop summary:
Antigen specific therapies for the prevention of type I diabetes mellitus. Diabetologia
38:A14-A17, 1995.
52.
Gill RG, Wolf L. Immunobiology of cellular transplantation. Cell Transplantation
370, 1995.
53.
Stegall MD, Ostrowska A, Haynes J, Karrer F, Kam I, Gill RG. Prolongation of islet
allograft survival with an antibody to vascular cell adhesion molecule 1. Surgery 118:366370, 1995.
54.
Wolf LA, Coulombe M, Gill RG. Donor antigen presenting cell independent rejection of
islet xenografts. Transplantation 60:1164-1170, 1995.
55.
Karrer FM, Gill R, Ostrowska A, Bolwerk A, Reitz B, Stegall M, Schroter G, Kam I,
Lafferty KJ. Purified hepatic parenchymal cells are non-immunogenic in vitro. Transplant.
Proc. 27:625-627, 1995.
Updated: January 16, 2011
4:361-
Ronald G. GILL
Page 10
56.
Coulombe M, Gill RG. T lymphocyte indifference to extrathymic islet allografts. J.
Immunol. 156:1998-2003, 1996.
57.
Gill RG. Immunobiology of islet transplantation. In: Type I Diabetes (Eisenbarth G and
Lafferty KJ, ed.), Oxford Univ. Press pp. 118-133, 1996.
58.
Gill RG, Coulombe M, Lafferty KJ. Pancreatic islet allograft immunity and tolerance: the
two-signal hypothesis revisited. Immunol. Rev. 149:75-96, 1996.
59.
Stegall MD, Lafferty KJ, Kam I, Gill RG. Evidence of autoimmunity in human allogeneic
islet transplantation. Transplantation 61:1272-1274, 1996.
60.
Stegall MD, Loberman Z, Ostrowska A, Coulombe M, Gill RG. Autoimmune destruction of
islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4
antibody. J. Surg. Res. 64:156-60, 1996.
61.
Coulombe M, Yang H, Guerder S, Flavell R, Lafferty K, Gill RG. Tissue immunogenicity:
the role of MHC antigen and the lymphocyte costimulator B7-1. J. Immunol. 157:47904795, 1996.
62.
Coulombe M, Yang H, Gill RG. Adoptive transfer of CD4 T cell dependent allograft
tolerance. Transplant. Proc. 29:1166-1167, 1997.
63.
Crawford M, Daniel D, Wegmann D, Yang H, Gill RG. Autoimmune islet damage mediated
by insulin-specific T cells. Transplant. Proc. 29:758-759, 1997.
64.
Karrer FM, Bilir G, Gill RG, Ostrowska A, Stegall M, Wachs M, Kam I. Cryopreserved
hepatocytes are poor stimulators of in vitro cytotoxicity. Transplant. Proc. 29:1111-1112,
1997.
65.
Gill RG. The role of deletion versus regulation in the maintenance of self-tolerance. Diab.
Met. Rev. 13:309-314, 1998.
66.
Gill RG. Direct and indirect pathways of immunity to pancreatic islet transplants.
Transplant. Rev. 12:85-95, 1998.
67.
Coulombe M, Yang H, Wolf LA, Gill RG. Tolerance to APC-depleted islet allografts is
CD4 T cell dependent. J. Immunol. 162:2503-2510, 1999.
68.
Gill RG. Antigen presentation pathways for immunity to islet transplants. Relevance to
immunoisolation. Annals N. Y. Acad. Sci. 875:255-260, 1999.
69.
Kelemen K, Crawford ML, Gill RG, Hutton JC, Wegmann D. Cellular immune response to
Phogrin in the NOD mouse: cloned T cells cause destruction of islet transplants. Diabetes.
48:1529-1534, 1999.
70.
Hunkeler D, Sun AM, Korbutt GS, Rajotte RV, Gill RG, Calafiore R, Morel P. Bioartificial
organs and acceptable risk. Nature Biotechnol. 17:1045, 1999.
71.
Pietra B, Rizeq M, Bolwerk A, Gill RG. CD4 T cells acutely reject cardiac allografts via
direct donor recognition. Transplant. Proc. 31:91, 1999.
72.
Stegall MD, Elices M, Pietra W, Shepard G, Gup C, Gill RG. Different roles for α4integrin/VCAM/fibronectin interactions in allograft rejection. Transplant. Proc.
31:786, 1999.
73.
Stegall MD, Elices M, Shepard G, Gup C, Ninova D, Ferguson D, Gill RG. The 2C T-cell
transgenic mouse: an in vivo model of allospecific cytotoxic T-cell activation and homing.
Transplant. Proc. 31:779, 1999.
Updated: January 16, 2011
Ronald G. GILL
Page 11
74.
Kawasaki E, Gill RG, Eisenbarth GS. Type I diabetes mellitus. In: Endocrine and Organ
Specific Autoimmunity (Eisenbarth GS, ed.), RG Landes Co. pp.149-182, 1999.
75.
Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG. Anti-LFA-1 therapy induces longterm islet allograft acceptance in the absence of IFNγ or IL-4. J. Immunol. 164:3627-3634,
2000.
76.
Diamond AS, Gill RG. An essential contribution by interferon-gamma to CD8+ T cellmediated rejection of pancreatic islet allografts. J. Immunol. 165:247-255, 2000.
77.
Pietra BA, Wiseman A, Bolwerk A, Rizeq M, Gill RG. CD4 T cell-mediated cardiac
allograft rejection requires donor but not host MHC Class II. J. Clin. Invest. 106:10031010, 2000.
78.
Stegall MD, Dean PG, Ninova D, Cohen AJ, Shepard GM, Gup C, Gill RG. α4 integrin in
islet allograft rejection. Transplantation 71:1549-1555, 2001.
79.
Gill RG. Cellular immune responses to xenografts. In: Xenotransplantation (Platt J, ed.),
ASM Press, Washington, D.C. pp. 99-115, 2001.
80.
Pietra BA, Gill RG. Immunobiology of cardiac allograft and xenograft transplantation.
Semin. Thorac. Cardiovasc. Surg. Pediatr. Surg. Annu. 4:123-157, 2001.
81.
Nicolls MR, Coulombe M, Gill RG. The basis of immunogenicity of endocrine allografts.
Crit. Rev. Immunol. 21:87-101, 2001.
82.
Gill RG. Use of small animal models for screening immunoisolation approaches to cellular
transplantation. Ann. N.Y Acad. Sci. 944:35-46, 2001.
83.
Wiseman AC, Pietra BA, Kelly BP, Rayat GR, Rizeq M, Gill RG. Donor IFN-γ receptors
are critical for acute CD4+ T cell-mediated cardiac allograft rejection. J. Immunol.
167:5457-5463, 2001.
84.
Nicolls MR, Coulombe M, Diamond AS, Beilke J, Gill RG. Interferon-γ is not a universal
requirement for islet allograft Survival. Transplantation 74:472-477, 2002.
85.
Nicolls MR, Coulombe M, Beilke J, Gelhaus HC, Gill RG. CD4 dependent generation of
dominant transplantation tolerance induced by simultaneous perturbation of CD154 and
LFA-1 pathways. J. Immunol. 169:4831-4839, 2002.
86.
Coulombe M, Gill RG. Immunobiology of endocrine gland transplantation. In:
Immunologically Mediated Endocrine Disease (Gill RG, Harmon J, Maclaren N, ed.),
Lippincott-Raven, Publishers pp. 83-102, 2002
87.
Gill RG. Animal models of pancreatic islet xenotransplantation. Curr. Opin. Organ
Transplantation 8:64-69, 2003.
88.
Nicolls MR, D’Antonio JM, Hutton JC, Gill RG, Czwornog JL, Duncan MW. Proteomics
as a tool for discovery: Proteins implicated in Alzheimer’s disease are highly expressed in
normal pancreatic islets. J. Proteome Res. 2:199-205, 2003.
89.
Rayat GR, Johnson ZA, Beilke JN, Korbutt GS, Rajotte RV, Gill RG. The degree of
phylogenetic disparity of islet grafts dictates the reliance of indirect CD4 T cell antigen
recognition for rejection. Diabetes 52:1433-1440, 2003.
90.
Rayat GR, Gill RG. Pancreatic islet xenotransplantation: barriers and prospects. Curr.
Diab. Rep. 3:336-343, 2003.
91.
Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, Devendra D, Beilke J, Gianani
R, Gill RG, Eisenbarth GS. Evidence for a primary islet autoantigen (preproinsulin 1) for
Updated: January 16, 2011
Ronald G. GILL
Page 12
insulitis and diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 100:10376-10381,
2003.
92.
Hunkeler D, Rajotte R, Grey D, Morel P, Skjak-Break G, Korbutt G, Gill R, Oberholzer J.
Bioartificial organ grafts: a view at the beginning of the third millennium. Artif. Cell Blood
Substit. Immobil. Biotechnol. 31:365-382, 2003.
93.
Johnson Z, Beilke J, Pietra B, Kelly B, Gill RG. Distinct requirements for host CD80/CD86
costimulatory molecules in cardiac versus islet rejection. Transplant. Proc. 36:1171-1172,
2004.
94.
Beilke J, Johnson Z, Kuhl N, Gill RG. A major role for host MHC class I antigen
presentation for promoting islet allograft survival. Transplant. Proc. 36:1173-1174, 2004.
95.
Wiseman AC, Gill RG. Current status of clinical islet transplantation: advances and
obstacles. Curr. Opin. Endocrinol. Diabetes 11:98-103, 2004.
96.
Grazia TJ, Pietra BA, Johnson ZA, Kelly BP, Plenter RJ, Gill RG. A two-step model of
acute CD4 T-cell mediated cardiac allograft rejection J. Immunol. 172:4751-7458, 2004.
97.
Coulombe M, Gill RG. Tolerance induction to pancreatic islet allografts. Curr. Opin.
Organ Transplant 9:258-263, 2004.
98.
Homann D, Gill RG. To help and help not. Nat. Immunol. 5:878-880, 2004.
99.
Coulombe M, Gill RG. The immunobiology of pancreatic islet transplantation. Adv. Exp.
Med. Biol. 552:154-169, 2004.
100.
Rayat GR, Gill RG. Indefinite survival of neonatal porcine islet xenografts by simultaneous
targeting of LFA-1 and CD154 or CD45RB. Diabetes 54:443-451, 2005.
101.
Murakawa T, Kerklo MM, Zamora MR, Wei Y, Gill RG, Henson PM, Grover FL, Nicolls
MR. Simultaneous LFA-1 and CD40 ligand antagonism prevents airway remodeling in
orthotopic airway transplantation: implications for the role of respiratory epithelium as a
modulator of fibrosis. J. Immunol. 174:3869-3879, 2005.
102.
Wiseman AC, Gill RG. The continuing progress and challenges of clinical islet
transplantation. Curr. Opin. Endo. Diab. 12:291-297, 2005.
103.
Kupfer TM, Crawford ML, Pham K, Gill RG. MHC-mismatched islet allografts are
vulnerable to autoimmune injury. J. Immunol. 175:2309-2316, 2005.
104.
Grazia TJ, Gill RG, Gelhaus HC, Doan AN, Sleater ML, Pietra BA. Perturbation of
leukocyte function-associated antigen-1/intercellular adhesion molecule-1 results in
differential outcomes in cardiac vs islet allograft survival. J. Heart Lung Transplant
24:1410-1414, 2005.
105.
Faubel S, Ljubanovic D, Poole B, Dursun B, He Z, Cushing S, Somerset H, Gill RG,
Edelstein CL. Peripheral CD4 T cell depletion is not sufficient to prevent ischemic acute
renal failure. Transplantation 80:643-649, 2005.
106.
Beilke JN, Kuhl NR, Van Kaer L, Gill RG. NK cells promote islet allograft tolerance via a
perforin-dependent mechanism. Nat. Med. 11:1059-1065, 2005.
107.
Nicolls MR, Gill RG. Mini review: LFA-1 (CD11a) as a therapeutic target. Am. J.
Transplant. 6:27-36, 2006.
108.
Gianani R, Putnam A, Still T, Yu L, Miao D, Gill RG, Beilke J, Supon P, Valentine A,
Iveson A, Dunn S, Eisenbarth GS, Hutton J, Gottlieb P, Wiseman A. Initial results of
Updated: January 16, 2011
Ronald G. GILL
Page 13
screening of non-diabetic organ donors for expression of islet autoantibodies. J. Clin.
Endocrin. Metab. 91:1855-1861, 2006.
109.
Mack CL, Tucker RM, Fontenot AP, Sokol RJ, Gill RG. Cellular and humoral
autoimmunity directed at bile duct epithelia in murine biliary atresia. Hepatology 44:12311239, 2006.
110.
Crossno JT Jr, Majka SM, Grazia T, Gill RG, Klemm DJ. Rosiglitazone promotes
development of a novel adipocyte population from bone marrow-derived circulating
progenitor cells. J. Clin. Invest. 116:3220-3228, 2006.
111.
Beilke JN, Gill RG. Frontiers in nephrology: the varied faces of natural killer cells in
transplantation contributions to both allograft immunity and tolerance. J. Am. Soc. Nephrol.
18:2262-2267, 2007.
112.
Sleater M, Diamond AS, Gill RG. Islet allograft rejection by contact-dependent CD8+ T
cells: perforin and FasL play alternate but obligatory roles. Am J. Transplant. 7:1927-1933,
2007.
113.
Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M, Coulombe MG, Liu E,
Elliott JF, Gill RG, Eisenbarth GS. Priming and effector dependence on insulin B:9-23
peptide in NOD islet autoimmunity. J. Clin. Invest. 117:1836-1843, 2007.
114.
Sarkar SA, Gunter J, Bouchard R, Reusch JE, Wiseman A, Gill RG, Hutton JC, Pugazhenthi
S. Dominant negative mutant forms of the cAMP response element binding protein induce
apoptosis and decrease the anti-apoptotic action of growth factors in human islets.
Diabetologia 50:1649-1659, 2007.
115.
Grazia TJ, Plenter RJ, Doan AN, Kelly BP, Weber SM, Kurche JS, Cushing SO, Gill RG,
Pietra BA. Spontaneous allograft tolerance in B7-deficient mice independent of preexisting
endogenous CD4+ CD25+ regulatory T-cells. Transplantation 83:1449-1458, 2007.
116.
Tucker RM, Hendrickson RJ, Mukaida N, Gill RG, Mack CL. Progressive biliary
destruction is independent of a functional tumor necrosis factor-alpha pathway in a rhesus
rotavirus-induced murine model of biliary atresia. Viral Immunol. 20:34-43, 2007.
117.
Sarkar SA, Wong R, Hackl SI, Moua O, Gill RG, Wiseman A, Davidson HW, Hutton JC.
Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes
56:72-79, 2007.
118.
Arefanian H, Tredget EB, Rajotte RV, Korbutt GS, Gill RG, Rayat GR. Combination of
anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term
survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD
mice. Cell Transplantation 16:787-798, 2007.
119.
Tredget EB, Arefanian H, Gill RG, Rajotte RV, Rayat GR. Monotherapy with anti-LFA-1
monoclonal antibody promotes long-term survival of rat islet xenografts. Cell
Transplantation 17:599-608, 2008.
120.
Kupfer T, Beilke JN, Pham K, Buhrman J, Gill RG. ‘Indirect’ acute islet allograft
destruction in NOD mice is independent of donor MHC and requires host B lymphocytes.
Transplant. Proc. 40:462-463, 2008.
121.
Ramirez-Victorino F, Beilke JN, Gill RG. Both innate and adaptive MHC class I-dependent
immunity impair long-term islet xenograft survival. Transplant. Proc. 40:557-558, 2008.
122.
Grazia, TJ, Plenter RJ, Weber SM, Lepper HM, Victorino F, Pietra BA, Gill RG. Acute
cardiac rejection requires directly cytotoxic CD4 T cells: parallel requirements for Fas and
perforin. Transplantation 89:33-39, 2010
Updated: January 16, 2011
Ronald G. GILL
Page 14
123.
Arefanian, H, Tredget EB, Rajotte RV, Gill RG, Korbutt GS, Rayat GR. Short-term
administrations of a combination of anti-LFA-1 and anti-CD154 monoclonal antibodies
induce tolerance to neonatal islet xenografts in mice. Diabetes 59:958-966, 2010
124.
Sklavos, MM, Bertera S, Tse HM, Bottino R, He J, Beilke JN, Coulombe MG, Gill RG,
Crapo JD, Trucco M, Piganelli JD. Redox modulation protects islets from transplant-related
injury. Diabetes 59:1730-1738, 2010
125.
Gill RG. Just how stable is allograft tolerance? Am. J. Transplant. 10:1499-1500, 2010
126.
Gill RG. NK cells: Elusive participants in transplantation immunity and tolerance. Curr.
Opin. Immunol. 22:649-654, 2010
127.
Grazia, TJ, Plenter RJ, Lepper HM, Victorino F, Miyamoto SD, Crossno JT, Pietra BA, Gill
RG, Zamora MR. Prolongation of cardiac allograft survival by a novel population of
autologous CD117+ bone marrow-derived progenitor cells. Am. J. Transplant. 11:34-44,
2011
Book Editor
1.
Immunologically Mediated Endocrine Diseases. Gill, RG, J Harmon, N Macleren, Eds.
Lippincott-Raven Publishers, 2002
Updated: January 16, 2011
Ronald G. GILL
Page 15
Scientific Abstracts
(since 1990 only)
1.
Hao, L, R Calcinaro, R Gill, K Lafferty, A Allison, E Eugui. The immunosuppressive drug
RS-61443 induces donor-specific allograft tolerance. XIII International Congress of the
Transplantation Society. San Francisco, California. August 19-24, 1990.
2.
Gill, R. Transforming growth factor β (TGF-β) prevents islet allograft rejection. XIII
International Congress of the Transplantation Society. San Francisco, California. August
19-24, 1990.
3.
Hao, L, M Coulombe, F Calcinaro, RG Gill, KJ Lafferty. Graft acceptance need not indicate
tolerance induction. Symposium on Tolerance Induction. Breckenridge, Colorado. January
13-16, 1991.
4.
Wolf, L, RG Gill. Xenoreactive T cell lines initiate islet graft destruction in vivo. XIVth
International Congress of the Transplantation Society. Paris, France. August 16-21, 1992.
5.
Gill, RG. The role of T lymphocyte subsets in islet xenograft rejection. XIVth International
Congress of the Transplantation Society. Paris, France. August 16-21, 1992.
6.
Coulombe, M, KJ Lafferty, RG Gill. Tolerance induction to non-immunogenic pancreatic
islet allografts. XIVth International Congress of the Transplantation Society. Paris, France.
August 16-21, 1992.
7.
LaRosa, FG, MJ Duggan, R Gill, M Coulombe, K Haskins, K Gosselin. Role of MHC
antigen expression on NOD pancreatic-islet cells in the development of type-1 diabetes.
FASEB Journal. 6:A1694, 1992
8.
Gill, RG, M Coulombe. Tolerance induction to peripheral (extrathymic) islet allografts.
Third Basic Sciences Symposium of The Transplantation Society. Big Sky, Montana.
September 8-11, 1993.
9.
Gill, RG, M Coulombe. Lack of peripheral (extrathymic) tolerance induction to pancreatic
islet allografts. American Association of Immunologists (AAI) Meeting. Denver, Colorado,
1993
10.
Coulombe, M., RG Gill. T cell indifference to extrathymic alloantigens. XVth World
Congress of the Transplantation Society. Kyoto, Japan. August 28-September 2, 1994.
11.
Wolf. L, D Daniel, M Coulombe, RG Gill. CD4+ T cells are sufficient to trigger islet
xenograft rejection. XVth World Congress of the Transplantation Society. Kyoto, Japan.
August 28-September 2, 1994.
12.
Gill, RG, M Coulombe. Islet xenograft survival in autoimmune diabetes. XVth World
Congress of the Transplantation Society. Kyoto, Japan. August 28-September 2, 1994.
13.
Scholl, M, D Daniel, D Wegmann, H Yang, RG Gill. Destruction of xenogeneic islet grafts
triggered by NOD-derived, insulin-specific T cells in vivo. 55th Meeting & Scientific
Sessions of the American Diabetes Association. Atlanta, Georgia. June 10-13, 1995
Diabetes 44 (Suppl. 1):10A (abstract), 1995
14.
Scholl, M, D Daniel, D Wegmann, H Yang, RG Gill. Xenogeneic islet cell destruction by
insulin-specific T lymphocytes. 5th International Congress on Pancreas and Islet
Transplantation. Miami Beach, Florida. June 18-22, 1995.
15.
Yang, H, M Coulombe, R Flavell, K Lafferty, RG Gill. The basis of tissue immunogenicity.
5th International Congress on Pancreas and Islet Transplantation. Miami Beach, Florida.
June 18-22, 1995.
Updated: January 16, 2011
Ronald G. GILL
Page 16
16.
Coulombe, M, H Yang, S Guerder, R Flavell, K Lafferty, R Gill. Tissue immunogenicity:
the role of antigen and costimulation. 4th Basic Sciences Symposium of the Transplantation
Society. Noordwijkerhout, The Netherlands. September 17-20, 1995.
17.
Scholl, M, D Daniel, D Wegmann, H Yang, RG Gill. Destruction of xenogeneic islet grafts
triggered by NOD-derived, insulin-specific T cells in vivo. The Third International Congress
for Xenotransplantation. Boston, Massachusetts. September 27-October 1, 1995.
18.
Coulombe M, H Yang, S Guerder, RA Flavell, KJ Lafferty, RG Gill. The basis of tissue
immunogenicity. American Association of Immunologists Meeting. New Orleans, LA. June
1-6, 1996.
19.
Scholl M, H Yang, D Daniel, D Wegmann, RG Gill. Autoimmune islet damage triggered by
CD4+ insulin specific T cells. American Association of Immunologists Meeting. New
Orleans, LA. June 1-6, 1996.
20.
Diamond, A, H Yang, A Bolwerk, RG Gill. Cytokine regulation of allograft destructive CD8
T cells. XVIth International Congress of the Transplantation Society. Barcelona, Spain.
August 25-30, 1996.
21.
Scholl, M, D Daniel, D Wegmann, H Yang, RG Gill. Autoimmune islet damage mediated
by insulin-specific T cells. XVIth International Congress of the Transplantation Society.
Barcelona, Spain. August 25-30, 1996.
22.
Coulombe, M, H Yang, RG Gill. Adoptive transfer of CD4 T-cell dependent allograft
tolerance. XVIth International Congress of the Transplantation Society. Barcelona, Spain.
August 25-30, 1996.
23.
Karrer, FM, B Bilir, RG Gill, A Ostrowska, M Stegall, M Wachs, I Kam. Cryopreserved
hepatocytes are poor stimulators of in vitro cytotoxicity. XVIth International Congress of
the Transplantation Society. Barcelona, Spain. August 25-30, 1996.
24.
Stegall, M, M Elices, G Shepard, J Haynes, M Wachs, I Kam, R Gill. Prevention of islet
allograft rejection by inhibiting lymphocyte extracellular matrix interactions. 57 th Annual
Meeting and Scientific Sessions, American Diabetes Association. Diabetes. 46(S1):63A,
1997.
25.
Diamond, A, H Yang, A Bolwerk, RG Gill. Mechanism of CD8-dependent rejection of
pancreatic islet allografts. 16th Annual Meeting of the American Society of Transplant
Physicians. Chicago, IL. May 10-17, 1997.
26.
Pietra, BA, L Wolf, M Coulombe, A Bolwerk, H Yang, RG Gill. CD4 T cells are sufficient
for cardiac but not pancreatic islet allograft rejection. 16th Annual Meeting of the American
Society of Transplant Physicians. Chicago, IL. May 10-17, 1997.
27.
Pietra, BA, RG Gill. CD4 T cells are sufficient for acute cardiac allograft and xenograft
rejection. 16th Annual Meeting of the American Society of Transplant Physicians. Chicago,
IL. May 10-17, 1997.
28.
Stegall, MD, C Gup, G Shepard, RG Gill. The role of a4 integrin/fibronectin interactions in
allospecific cytotoxic T cell activation and homing--initial studies in the 2C T-cell receptor
transgenic. 17th Annual Meeting of the American Society of Transplant Physicians.
Chicago, IL. May 10-13, 1998.
29.
Coulombe, M., H Yang, M Nicolls, A Bolwerk, R Araujo, and RG Gill. Transferable
allograft tolerance induced by anti-LFA-1 (CD11a) therapy. 17th Annual Meeting of the
American Society of Transplant Physicians. Chicago, IL. May 10-13, 1998.
Updated: January 16, 2011
Ronald G. GILL
Page 17
30.
Yang, H, A Bolwerk, D Walborn, and RG Gill. CD4-mediated islet xenograft rejection
requires indirect antigen recognition. 17th Annual Meeting of the American Society of
Transplant Physicians. Chicago, IL. May 10-13, 1998.
31.
Pietra, BA, M Rizeq, RG Gill. Chronic cardiac allograft rejection is independent of donor
MHC class II antigens. 17th Annual Meeting of the American Society of Transplant
Physicians. Chicago, IL. May 10-13, 1998.
32.
Pietra, BA, M Rizeq, RG Gill. Acute CD4-mediated cardiac allograft rejection requires
donor class II MHC molecules. 17th Annual Meeting of the American Society of Transplant
Physicians. Chicago, IL. May 10-13, 1998.
33.
Stegall, MD, G Shepard, C Gup, RG Gill. Long-term protection against adoptive transfer of
IDDM in the NOD mouse by blocking multiple integrins. 58th Scientific Session of the
American Diabetes Association. June 13-16, 1998. Diabetes 47(suppl 1): A199, 1998
34.
Pietra, RG, M Rizeq, RG Gill. CD4 T cells reject cardiac allografts via direct donor
recognition. XVII World Congress of the Transplantation Society. Montreal, Canada, July
12-17, 1998.
35.
Stegall, MD, W Pietra, G Hepard, C Gup, RG Gill. Different roles for α4-integrin/VCAM-1
and α4/Fibronectin interactions in allograft rejection. XVII World Congress of the
Transplantation Society. Montreal, Canada, July 12-17, 1998.
36.
Stegall, MD, G Shepard, C Gup, RG Gill. The 2C T-cell transgenic mouse: an in vivo model
of allospecific cytotoxic T cell activation and homing. XVII World Congress of the
Transplantation Society. Montreal, Canada, July 12-17, 1998.
37.
Yang, H, A Bolwerk, D Walborn, RG Gill. Islet xenograft rejection requires indirect antigen
recognition. XVII World Congress of the Transplantation Society. Montreal, Canada, July
12-17, 1998.
38.
Diamond, A, RG Gill. Biphasic Roles for IFNγ in Islet Allograft Immunity and Tolerance.
Keystone Symposium, Molecular and Cellular Biology of Transplantation. Lake Tahoe,
Nevada, March 21-26, 1999
39.
Gill, RG, A Bolwerk, H Yang. Indefinite Islet Xenograft Survival Induced by Anti-LFA-1
(CD11a) Therapy. Keystone Symposium, Molecular and Cellular Biology of
Transplantation. Lake Tahoe, Nevada, March 21-26, 1999
40.
Pietra, BA, M Rizeq, RG Gill. CD4 T cells can provide help via the indirect pathway to
reject MHC class II-/- hearts. 18th Annual Meeting of the American Society of
Transplantation, May 15-19, 1999. Transplantation 67:S7, 1999
41.
Wiseman, AC, BA Pietra, MA Rizeq, RG Gill. The CD4+ effector T cell requires IFN-γ to
mediate acute cardiac allograft rejection. 18th Annual Meeting of the American Society of
Transplantation, May 15-19, 1999 (AST young investigator award). Transplantation 67:S22,
1999
42.
Diamond, A, RG Gill. Biphasic roles for IFNγ in islet allograft immunity and tolerance.
18th Annual Meeting of the American Society of Transplantation, May 15-19, 1999.
Transplantation 67:S23, 1999
43.
Nicolls, MR, M Coulombe, RG Gill. IFNγ and IL-4 are not required for anti-LFA-1-induced
islet allograft prolongation. 18th Annual Meeting of the American Society of
Transplantation, May 15-19, 1999 (AST young investigator award). Transplantation 67:S35,
1999
Updated: January 16, 2011
Ronald G. GILL
Page 18
44.
Crawford, M, K Haskins, RG Gill. Fas (CD95)-independent islet allograft destruction
mediated by CD4+ islet-specific T cells. 18th Annual Meeting of the American Society of
Transplantation, May 15-19, 1999. Transplantation 67:S36, 1999
45.
Kalayanamit, T, A Bolwerk-Varra, A Valentine, RG Gill. Islet xenograft prolongation
mediated by anti-CD45RB monotherapy. 18th Annual Meeting of the American Society of
Transplantation, May 15-19, 1999. Transplantation 67:S138, 1999
46.
Gill, RG, A Bolwerk, H Yang. Indefinite islet xenograft survival induced by anti-LFA-1
(CD11a) therapy. 18th Annual Meeting of the American Society of Transplantation, May
15-19, 1999 (AST poster of distinction). Transplantation 67:S138, 1999
47.
Pietra, BA, RG Gill, A Wiseman, M Rizeq, J Robbins, MM Boucek, DP Nelson. FasL
interferes with effector CD4 T cell mediated rejection of cardiac allografts. 18th Annual
Meeting of the American Society of Transplantation, May 15-19, 1999. Transplantation
67:S206, 1999
48.
Nelson, DP, BA Pietra, E Setser, A Akanbi, R Klevitsky, H Osinska, RG Gill, J Robbins.
Life in the Fas L(ane): cardiac FasL expression is both pro-inflammatory and immuneprotective. Circulation 100 (suppl):284, 1999
49.
Gill, RG, J Beilke, and M Coulombe. Contribution to acute islet allograft rejection by CD4dependent indirect recognition of donor antigens. 1st Joint Meeting of the American Society
of Transplantation. May 13-17, 2000. Chicago, IL.
50.
Malecki, TM, M Crawford, and RG Gill. Islet allograft destruction by islet-specific CD4 T
cells occurs via indirect antigen presentation. 1st Joint Meeting of the American Society of
Transplantation. May 13-17, 2000. Chicago, IL.
51.
Kalayanamit, T, J Beilke, and RG Gill. Maintenance of islet xenograft prolongation by antiCD45RB therapy requires CD4 T cells. 1st Joint Meeting of the American Society of
Transplantation. May 13-17, 2000. Chicago, IL.
52.
Wiseman, AC, BA Pietra, and RG Gill. Graft IFN-γ receptors are necessary for the effector
phase of CD4-mediated acute cardiac allograft rejection. 1st Joint Meeting of the American
Society of Transplantation. May 13-17, 2000. Chicago, IL.
53.
Diamond, AS and RG Gill. Resistance to induction of long-term allograft survival in IFNγdeficient mice maps to hyperaggressive CD8 T cell subset. 1st Joint Meeting of the American
Society of Transplantation. May 13-17, 2000. Chicago, IL.
54.
Coulombe M, M Nicolls, J Beilke, A Bolwerk, and RG Gill. Efficacy of allograft tolerance
induced by anti-LFA-1 therapy maps to non-MHC genes. 1st Joint Meeting of the American
Society of Transplantation. May 13-17, 2000. Chicago, IL.
55.
Beilke J, N Kuhl, and RG Gill. Prolongation of islet xenografts by anti-LFA-1 therapy is
CD4-T cell dependent. 1st Joint Meeting of the American Society of Transplantation. May
13-17, 2000. Chicago, IL.
56.
Rayat, GR, JN Beilke, N Kuhl, A Bolwerk, RG Gill. Resistance to islet xenograft
prolongation in NOD mice is independent of autoimmune disease status. The 8th Congress of
the International Pancreas and Islet Transplant Association. Act. Chir. Austiraca. 33 (Suppl
174): 51, 2001
57.
Rayat, GR, Z Johnson, GS Korbutt, RV Rajotte, RG Gill. CD4+ T cells are sufficient for
rejection of neonatal porcine islet xenografts and are dependent on host class II MHC
molecules. The 8th Congress of the International Pancreas and Islet Transplant Association.
Act. Chir. Austiraca. 33 (Suppl 174): 57, 2001
Updated: January 16, 2011
Ronald G. GILL
Page 19
58.
Rayat, GR, JN Beilke, GS Korbutt, RV Rajotte, RG Gill. Hierarchy of dependency on host
class II MHC molecules in rejection of pancreatic islet allo- and xenografts. The 8th
Congress of the International Pancreas and Islet Transplant Association. Act. Chir.
Austiraca. 33 (Suppl 174): 76, 2001
59.
Kalayanamit, T, J Beilke, RG Gill. Islet xenograft prolongation by anti-CD45RB therapy
requires the continued presence of peripheral CD4 T cells. VI Congress of the International
Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 6, 2001
60.
Beilke, J, RG Gill. CD4 T cell dependent survival of islet xenografts induced by anti-LFA-1
(CD11a) therapy. VI Congress of the International Xenotransplantation Association.
Chicago, IL. Xenotransplantation 8(S1): 6, 2001
61.
Johnson, ZA, RG Gill. Neither NK cells nor host innate immune signaling through the
common cytokine receptor gamma chain are required for islet xenograft rejection. . VI
Congress of the International Xenotransplantation Association. Chicago, IL.
Xenotransplantation 8(S1): 9, 2001
62.
Rayat, GR, N Kuhl, RG Gill. Resistance to islet xenograft prolongation in NOD mice is
independent of autoimmune syndrome status. VI Congress of the International
Xenotransplantation Association. Chicago, IL. Xenotransplantation 8(S1): 2, 2001
63.
Rayat, GR, JN Beilke, GS Korbutt, RV Rajotte, RG Gill. A hierarchy in the requirement for
host MHC class II molecules in the rejection of pancreatic islet allo- and xenografts. VI
Congress of the International Xenotransplantation Association. Chicago, IL.
Xenotransplantation 8(S1): 39, 2001
64.
Rayat, GR, ZA Johnson, GS Korbutt, RV Rajotte, RG Gill. CD4+ T cells are sufficient for
triggering rejection of neonatal porcine islet xenografts and are dependent on host class II
MHC molecules. VI Congress of the International Xenotransplantation Association.
Chicago, IL. Xenotransplantation 8(S1): 51, 2001
65.
Rayat, GR, GS Korbutt, RV Rajotte, RG Gill. Combinational therapies for long-term islet
xenograft survival. VI Congress of the International Xenotransplantation Association.
Chicago, IL. Xenotransplantation 8(S1): 123, 2001
66.
Wiseman, AC, MR Nicolls, AS Diamond, J Beilke, RG Gill. The contribution of IFN-γ to
islet allograft survival following anti-CD4 therapy. 10th Anniversary Congress of the Cell
Transplant Society. Keystone, CO . Oct, 14-17, 2001. Cell Transplantation 10:527
67.
Rayat, GR, GS Korbutt, RV Rajotte, RG Gill. Combination of anti-LFA 1 antibody with
anti-CD45RB antibody or anti-CD154 antibody promotes long-term porcine islet xenograft
survival. 10th Anniversary Congress of the Cell Transplant Society. Keystone, CO . Oct, 1417, 2001. Cell Transplantation 10:526-7
68.
Nicolls, MR, M Coulombe, J Beilke, RG Gill. A strategic combination of anti-LFA-1 and
anti-CD40L monoclonal antibody therapy induces dominant tolerance in experimental islet
transplantation. 10th Anniversary Congress of the Cell Transplant Society. Keystone, CO .
Oct, 14-17, 2001. Cell Transplantation 10:523
69.
Wiseman, AC, N Kuhl, J Beilke, RG Gill. Anti-CD4-induced islet allograft survival
requires donor IFN-g receptors. Am. J. Transplant. 2(Suppl1):153, 2002
70.
Gelhaus, HC, MR Nicolls, RG Gill. Deletion of graft specific CD8+ T cells is not necessary
for prolonged islet allograft survival. American Transplant Congress 2002. Am. J.
Transplant. 2(Suppl1):447, 2002
Updated: January 16, 2011
Ronald G. GILL
Page 20
71.
RG Gill, J Beilke N Kuhl. Islet allograft prolongation following costimulation blockade
requires an intact host MHC class I presentation pathway. American Transplant Congress
2002. Am. J. Transplant. 2(Suppl1):210, 2002
72.
MR Nicolls, M Coulombe, J Beilke, RG Gill. Dominant transplantation tolerance does not
require elimination of donor-specific T cells in vivo. American Transplant Congress 2002.
Am. J. Transplant. 2(Suppl1):212, 2002.
73.
Johnson, ZA, GR Rayat, RG Gill. Profound CD4+ T cell mediated islet xenograft rejection
in the absence of NK cell reactivity. American Transplant Congress 2002. Am. J.
Transplant. 2(Suppl1); Abstract #520, 2002
74.
Malecki, TM, GR Rayat, RG Gill. Autoreactive islet-specific mouse CD4 T cells coordinate
the destruction of islet xenografts in vivo. American Transplant Congress 2002. Am. J.
Transplant. 2(Suppl 1):466, 2002
75.
Rayat GR, GS Korbutt, RV Rajotte, RG Gill. Combinations of monoclonal antibodies
promote long-term survival of neonatal porcine islet xenografts. American Transplant
Congress. Am. J. Transplant. 2(Suppl1):448, 2002
76.
Rayat GR, Korbutt, GS, Rajotte, RG Gill. Combinations of monoclonal antibodies promote
long-term survival of neonatal porcine islet xenografts. 2002 Canadian Diabetes Association
Meeting. Canad. J. Diabetes 26(3): Abtract#40, 2002
77.
Pietra, BA, AZ Johnson, BP Kelly, SO Cushing, RG.Gill. Spontaneous door-specific
tolerance to cardiac allografts in the absence of host CD80/86. American Transplant
Congress of the ASTS and AST. May 30-June 4, 2003, Washington, D.C. Am. J.
Transplant. 3 (S5):194, 2003
78.
Gelhaus, HC, RG Gill. Direct impact of tolerizing therapies on graft-destructive CD8 T
cells.. American Transplant Congress of the ASTS and AST. May 30-June 4, 2003,
Washington, D.C. Am. J. Transplant. 3 (S5):262, 2003.
79.
Nicolls, MR, JM DAntonio, MM Kerklo, NE Gomez, JC Hutton, RG Gill, JL Czwornog,
MW Duncan. Proteomics as a tool for discovery: proteins implicated in Alzheimer’s disease
are highly expressed in normal pancreatic islets. American Transplant Congress of the
ASTS and AST. May 30-June 4, 2003, Washington, D.C. Am. J. Transplant. 3 (S5):410,
2003
80.
Gelhaus, HC, RG Gill. Paradoxical rescue of donor-specific T cells is associated with active
allograft tolerance. American Transplant Congress of the ASTS and AST. May 30-June 4,
2003, Washington, D.C. Am. J. Transplant. 3 (S5):419, 2003
81.
Grazia, TJ, RG Gill, J Jensen, JN Jensen, BA Pietra. Contribution of MHC class II
expression by donor hematopoietic cells in CD4-mediated cardiac allograft rejection.
American Transplant Congress of the ASTS and AST. May 30-June 4, 2003, Washington,
D.C. Am. J. Transplant. 3 (S5):539, 2003
82.
Beilke, J, Z Johnson, RG Gill. An intact host MHC class I pathway is necessary for longterm islet allograft survival. American Association of Immunologists (AAI) 90 th Anniversary
Annual Meeting. Denver, CO May 6-10, 2003. FASEB J. 17:C63-64, 2003.
83.
Rayat, GR, JN Beilke, RG Gill. Combination of Rapamycin and anti-LFA-1 prevents
rejection of rat islet xenografts. 9th Congress of the International Pancreas and Islet
Transplant Association (IPITA). July 8-11, 2003. Dublin, Ireland
Updated: January 16, 2011
Ronald G. GILL
Page 21
84.
Johnson, Z, J Beilke, B Pietra, B Kelly, RG Gill. Distinct requirements for host CD80/CD86
costimulatory molecules in cardiac versus islet rejection. 9th Congress of the International
Pancreas and Islet Transplant Association (IPITA). July 8-11, 2003. Dublin, Ireland
85.
Rayat, GR, J Beilke, RG Gill. Genetic resistance of NOD mice to islet allograft versus
xenograft prolongation. 9th Congress of the International Pancreas and Islet Transplant
Association (IPITA). July 8-11, 2003. Dublin, Ireland
86.
Rayat, GR, GS Korbutt, RV Rajotte, RG Gill. Strategic combinations of monoclonal
antibodies promote long-term survival of neonatal porcine islet xenografts and is associated
with decreased anti-porcine antibody production. 9th Congress of the International Pancreas
and Islet Transplant Association (IPITA). July 8-11, 2003. Dublin, Ireland
87.
Gill, RG, J Rawson, M Coulombe. B lymphocytes facilitate islet allograft rejection but are
not required for tolerance resistance in NOD mice. American Transplant Congress, May 1519, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):186, 2004.
88.
Sleater, M., AS Diamond, A Bolwerk, RG Gill. Perforin and Fas-L (CD95L) form parallel,
complementary pathways of CD8 T cell mediated islet allograft rejection. American
Transplant Congress; May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):246,
2004.
89.
Johnson, Z, J Beilke, B Pietra, B Kelly, RG Gill. Distinct requirements for host CD80/CD86
costimulatory molecules in cardiac versus islet rejection. American Transplant Congress,
May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):413, 2004.
90.
Pietra, BA, RJ Plenter, SO Cushing, A Doan, RG Gill. Long-term cardiac allograft survival
after dual therapy with anti-CD40L and anti-LFA-1 antibodies. American Transplant
Congress, May 15-19, 2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):430, 2004.
91.
Nicolls, MR, MM Kerklo, N Gomez, J Beilke, MW Duncan, RG Gill. Protein biomarkers of
metabolic stress in islet transplantation. American Transplant Congress, May 15-19, 2004,
Boston, MA. Am. J. Transplant. 4(Suppl 8):469, 2004.
92.
Beilke, JN, NR Kuhl, ZA Johnson, RG Gill. An essential requirement for an intact host
MHC class I pathway in islet allograft survival. American Transplant Congress, May 15-19,
2004, Boston, MA. Am. J. Transplant. 4(Suppl 8):581, 2004.
93.
Grazia, TJ, BA Pietra, ZA Johnson, RJ Plenter, RG Gill. A two step model of acute CD4mediated cardiac allograft rejection. American Transplant Congress, May 15-19, 2004,
Boston, MA. Am. J. Transplant. 4(Suppl 8):584, 2004.
94.
Beilke*, JN, NR Kuhl, RG Gill. NK cells play an essential role for anti-CD154 induced islet
allograft tolerance. 7th International Congress of the Cell Transplant Society, Nov. 17-20,
2004. Boston, MA (Awarded as one of the top 5 conference abstracts)
95.
Sleater, M, AS Diamond, RG Gill. Perforin and FasL/Fas are the predominant effectors of
CD8 T cell-mediated islet allograft rejection. 7th International Congress of the Cell
Transplant Society, Nov. 17-20, 2004. Boston, MA.
96.
Beilke, J, N Kuhl, P Supon, R Gill, A Wiseman. Improved islet cell recovery from
donors with a low body mass index: toward making every organ count. 7th
International Congress of the Cell Transplant Society, Nov. 17-20, 2004. Boston, MA
87.
Gill, RG, K Phan, J Rawson, M Coulombe. B lymphocytes can be dispensable for both the
induction and maintenance of islet allograft tolerance. 7th International Congress of the Cell
Transplant Society, Nov. 17-20, 2004. Boston, MA
Updated: January 16, 2011
Ronald G. GILL
Page 22
88.
Wiseman, AC, J Beilke, N Kuhl, PA Supon, RG Gill. Prolonged warm digestion of human
pancreata improves islet cell recovery and transplant rates from young, nonobese donors.
10th Congress of the International Pancreas and Islet Transplant Association (IPITA). May 6,
2005. Geneva, Switzerland
89.
Beilke, JN, NR Kuhl, RG Gill. An essential role for NK cells in anti-CD40 ligand induced
islet allograft tolerance. American Transplant Congress, May 21-25, 2005. Seattle, WA.
Am. J. Transplant 5(Suppl 11):279, 2005 (Highlighted in What’s new, What’s hot meeting
summary address
90.
Beilke, JN, NR Kuhl, RG Gill. A requirement for NK-derived perforin in islet allograft
tolerance. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J.
Transplant 5(Suppl 11):279, 2005
91.
Kupfer, TM, ML Crawford, RG Gill. IFN-γ is a key component of CD4 T cell-mediated
recurrent autoimmune pathogenesis to islet allografts. American Transplant Congress, May
21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):309, 2005
92.
RG Gill, K Pham, J Rawson, M Coulombe. B lymphocytes are not required for the
induction or maintenance of islet allograft tolerance. American Transplant Congress, May
21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):312, 2005
93.
Plenter, R.J., AN Doan, TJ Grazia, RG Gill, BA Pietra. Indirect CD4 T-cells mediate
cardiac xenograft rejection. American Transplant Congress, May 21-25, 2005. Seattle, WA.
Am. J. Transplant 5(Suppl 11):371, 2005
94.
Nicolls, MR, T Murakawa, MM Kerklo, RG Gill, FL Grover, MR Zamora. The state of the
respiratory epithelium correlates with airway fibrosis in allogeneic orthotopic tracheal
transplantation. American Transplant Congress, May 21-25, 2005. Seattle, WA. Am. J.
Transplant 5(Suppl 11):441, 2005
95.
Sleater, M., AS Diamond, RG Gill. Both direct CD8+ and direct CD4+ T cells reject islet
allografts via perforin and FasL/Fas. American Transplant Congress, May 21-25, 2005.
Seattle, WA. Am. J. Transplant 5(Suppl 11):480, 2005.
96.
Sleater M, Gill RG. Activated donor-MHC class II-restricted CD4+ T cells are sufficient to
mediate islet allograft rejection. American Association of Immunologists 2005, Oral
Presentation (April, 2005. San Diego, CA).
97.
Wiseman, AC, J Beilke, N Kuhl, P Supon, RG Gill. Improved islet cell recovery from
donors with a low body mass index: toward making every organ count. American Transplant
Congress, May 21-25, 2005. Seattle, WA. Am. J. Transplant 5(Suppl 11):512, 2005
98.
Rayat, G, T Kobayashi, G Harb, R Rajotte, G Korbutt, R Gill. Prolonged survival of
microencapsulated neonatal porcine islets in mice treated with a combination of anti-CD154
and anti-LFA-1 monoclonal antibodies. 8th International Xenotransplantation Association
(IXA) Congress, Sept 10-14, 2005. Goteborg, Sweden. Xenotransplantation 12:398, 2005
99.
Nakayama, M., J Beilke, J Jasinski, D Miao, M Kobayashi, L Yu, R Gianani, E Liu, R Gill,
G Eisenbarth. Rapid restoration of anti-islet autoimmunity following transplantation of islets
with native insulin sequence versus insulin gene knockout islets with mutated B16:A insulin.
FOCIS 6th Annul Meeting. June 1-5, 2006. Clin. Immunol. 119(Suppl): S162-3.
100.
Nakayama, M, J Beilke, J Jasinski, E Liu, R Gill, G Eisenbarth. The destruction of islets
lacking native insulin genes with mutated B16A insulin transgene by diabetic NOD mice.
FOCIS 6th Annul Meeting. June 1-5, 2006. Clin. Immunol. 119(Suppl): S171-2, 2006.
Updated: January 16, 2011
Ronald G. GILL
Page 23
101.
Kurche, J, JT Hill, SM Weber, J Buhrman, RG Gill. Regulatory CD4+CD25+ T cells
restrain alloreactive CD8+ T cells via a shared antigen presenting cell. 2006 World
Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 82.
102.
Beilke, JN, L Edwards, RG Gill. NK cells restrain CD8 T cells during tolerance induction to
islet allografts. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006
Supplement p. 367.
103.
Plenter, RJ, TJ Grazia, KS Hill, JN Beilke, RG Gill, BA Pietra. Anti-LFA-1 induced cardiac
allograft tolerance induction requires host MHC class I expression but not CD1-restricted
NKT-cells. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006
Supplement p. 369.
104.
Beilke, JN, F Ramirez, RG Gill. Host B7 (CD80/CD86) costimulatory molecules are
dispensable for both immunity and tolerance to islet allografts. 2006 World Transplant
Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 418.
105.
Kerklo, MM, RG Gill, AC Wiseman, MR Zamora, MR Nicolls. A determination of human
islet viability for transplantation using difference-in-gel electrophoresis (DIGE) proteomics.
2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p.
422.
106.
Lakey, JRT, J Kaddis, N Ruel, D Quian, RG Gill, F Kandeel, A Naji, A Omer, AO Gaber,
MA Hardy, BJ Hering, T Mohanakumar, J Reems, C Ricordi, DR Salomon, GC Weir, JC
Niland. 2006 World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006
Supplement p 573.
107.
Plenter, RJ, TJ Grazia, KS Hill, DP Nelson, RG Gill, BA Pietra. Ectopic expression of FasL
on cardiomyocytes renders cardiac allografts resistant to rejection by contact-dependent
effector CD4+ T-cells. 2006 World Transplant Congress. July 22-27, 2006. Am. J.
Transplant. 2006 Supplement p. 603.
108.
Sleater, ML, JS Kurche, F Ramirez, RG Gill. Indirect (cross-primed) CD8+ T cells are
insufficient to reject islet allografts. 2006 World Transplant Congress. July 22-27, 2006. Am.
J. Transplant. 2006 Supplement p. 758.
109.
Sleater, ML, SM Weber, RG Gill. Direct (donor MHC-restricted) CD4 T cells are sufficient
to mediate the rejection of islet allografts. 2006 World Transplant Congress. July 22-27,
2006. Am. J. Transplant. 2006 Supplement p. 758.
110.
Kupfer, TM, RG Gill. NOD antigen-presenting-cells are sufficient to render islets
vulnerable to autoimmune injury in an MHC-disparate environment. 2006 World Transplant
Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 760.
111.
Kupfer TM, K Pham, JN Beilke, RG Gill. Acute destruction of islet allografts in NOD mice
is donor MHC-independent. 2006 World Transplant Congress. July 22-27, 2006. Am. J.
Transplant. 2006 Supplement p. 996.
112.
Grazia TJ, RJ Plenter, AN Doan, KS Hill, RG Gill, BA Pietra. Perforin and Fas/FasL form
alternate and obligate pathways of CD4+ T cell mediated cardiac allograft rejection. 2006
World Transplant Congress. July 22-27, 2006. Am. J. Transplant. 2006 Supplement p. 10171018.
113.
Arefanian G, R Petriw, EB Tredget, RG Gill, RV Rajotte, GS Korbutt, GR Rayat. Speciesspecific tolerance to neonatal porcine islet xenograft induced by combination of anti-LFA-1
and anti-CD154 monoclonal antibodies. 2006 World Transplant Congress. July 22-27, 2006.
Am. J. Transplant. 2006 Supplement p. 1046.
Updated: January 16, 2011
Ronald G. GILL
Page 24
114.
Kupfer TM, ML Crawford, RG Gill. IFN- but not TNFR1 or IL-1R, is a key component of
recurrent autoimmune pathogenesis to islet allografts mediated by indirect, islet-autoreactive
CD4 T cells. ADA 66th Scientific Sessions. June 22-26, 2006. Chicago IL.
115.
Arefanian H, Petriw R, Tredget EB, Gill RG, Rajotte RV, Korbutt GS, Rayat GR.
Combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induces tolerance to
neonatal porcine islet xenografts. Canadian Society of Transplantation, 2007 Annual
Scientific Meeting (March 15-18, Banff, AB). Abstract Book, Page 25 (Abst. #048-B), 2007.
116.
Plenter RJ, Grazia TJ, Hill KS, Gill RG, Pietra BA. Cardiac allograft tolerance induction:
are host MHC class I expression, CD8+ T-cells, NK cells and NKT-cells required? 2007
American Transplant Congress (San Francisco, CA, May 5-9, 2007). Am. J. Transplant.
7(Suppl. 2):222 (Abst. #290), 2007.
117.
Grazia TJ, Plenter RJ, Hill KS, Gill RG, Pietra BA. Spontaneous cardiac allograft tolerance
in B71/2-deficient recipients involves peripherally induced CD4+CD25+Foxp3+regulatory
T-cells, but does not require thymic-derived endogenous CD4+CD25+Foxp3+ regulatory Tcells. 2007 American Transplant Congress (San Francisco, CA, May 5-9, 2007). Am. J.
Transplant. 7(Suppl. 2):488 (Abst. #1330), 2007.
118.
Gill RG, Ramirez-Victorino F, Beilke JN. Impairment of long-term islet xenograft survival
by both innate (NK) and adaptive (CD8) MHC class I-dependent immunity. 2007 American
Transplant Congress (San Francisco, CA, May 5-9, 2007). Am. J. Transplant. 7(Suppl. 2):
582 (Abst. #1691), 2007. (Poster of distinction award)
119.
Arefanian H, Petriw R, Tredget E, Gill R, Rajotte R, Rayat G. Combination of anti-LFA-1
and anti-CD154 monoclonal antibodies induces species-specific tolerance to neonatal
procine islet xenografts by regulatory T cells. Tom Williams Surgical Research Day,
Department of Surgery, University of Alberta (Edmonton, AB, May 11, 2007). Abstract
Book, Page 24, 2007.
120.
Tucker R, Gill RG, Mack C. Generation of T-cell hybridomas specific for bile duct and
Rhesus rotavirus antigens in a murine model of biliary atresia. Immunology 2007, 94th
Annual Meeting of the American Association of Immunologists (Miami, FL, May 18-22,
2007). J. Immunol. 178:130.27, 2007.
121.
Gill RG. Immunity to pancreatic islet allografts. 2007 CTS-IPITA-IXA 2007 Joint
Conference (Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:397
(Abst. #204.1), 2007.
122.
Ramirez-Victorio F, Beilke JN, Gill RG. Both innate and adaptive MHC class I-dependent
immunity impair long-term islet xenograft survival. 2007 CTS-IPITA-IXA 2007 Joint
Conference (Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:434-435
(Abst. #407.1), 2007.
123.
Kupfer T, Beilke JN, Pham K, Buhrman J, Gill RG. ‘Indirect’ acute islet allograft
destruction in NOD mice is independent of donor MHC and requires host B lymphocytes.
2007 CTS-IPITA-IXA 2007 Joint Conference (Minneapolis, MN, September 15-20, 2007).
Xenotransplantation 14:435 (Abst. #407.3), 2007.
124.
Arefanian H, Tredget EB, Gill RG, Rajotte RV, Rayat GR. Combination of anti-LFA-1 and
anti-CD154 monoclonal antibodies induces species-specific tolerance to neonatal porcine
islet xenografts by regulatory T cells. 2007 CTS-IPITA-IXA 2007 Joint Conference
(Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:513 (Abst. #PN1404),
2007.
Updated: January 16, 2011
Ronald G. GILL
Page 25
125.
Arefanian H, Tredget EB, Gill RG, Rajotte RV, Rayat GR. Induction of tolerance to
neonatal porcine islet xenografts using a combination of anti-LFA-1 and anti-CD154 does
not require CD4+ or CD8+ T cells. 2007 CTS-IPITA-IXA 2007 Joint Conference
(Minneapolis, MN, September 15-20, 2007). Xenotransplantation 14:513 (Abst. #PN1405),
2007.
126.
Arefanian H, Tredget EB, Gill RG, Rajotte RV, Rayat GR. Induction tolerance to neonatal
porcine islet xenografts using a combination of anti-LFA-1 and anti-CD154 does not require
CD4+ or CD8+ T cells. Alberta Diabetes Institute 4th Annual Research Retreat (September
28, 2007, Edmonton, AB). Abstract Book, pg. 20, 2007.
127.
Kurche JS, Weber SM, Buhrman JB, Kedi RM, Gill RG. Regulatory T cells from transgenic
mice express multiple T cell receptors, confounding studies of their antigen specificity. 13th
International Congress of Immunology (Rio de Janeiro, Brasil, August 21-25, 2007). J.
Investigative Med. 56:227-228 (Abst. #373), 2008.
128.
Arefanian H, Tredget EE, Mok D, Rajotte RV, Gill RG, Korbutt GS, Rayat GR.
Combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induces tissue-specific
tolerance to neonatal porcine islet xenografts. Tom Williams Surgical Research Day,
Department of Surgery, University of Alberta (Edmonton, AB, May 9, 2008). Abstract
Book, Page 44, 2008.
129.
Arefanian H, Tredget EB, Rajotte RV, Gill RG, Korbutt GS, Rayat GR. Combination of
anti-LFA-1 and anti-CD154 monoclonal antibodies induces tissue-specific tolerance to
neonatal porcine islet xenografts. XXII International Congress of The Transplantation
Society (Sydney, Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):106 (Abst.
#299), 2008.
130.
Balamurugan AN, Lewis EC, Wiseman AC, Pugazhenthi S, Sarkar SA, Dinarello CA, Gill
RG. Effect of in vitro treatment of isolated human islets with human alpha1-antitrypsin.
XXII International Congress of The Transplantation Society (Sydney, Australia, August 1014, 2008). Transplantation 86(Suppl 2S):445 (Abst. #1320), 2008.
131.
Gill RG, Kupfer T, Beilke J, Pham K, Buhrman J. B lymphocyte dependent rejection of islet
allografts via indirect recognition in autoimmune-prone NOD mice. XXII International
Congress of The Transplantation Society (Sydney, Australia, August 10-14, 2008).
Transplantation 86(Suppl 2S):143 (Abst. #405), 2008.
132.
Gill RG, Beilke JN, Kuhl NR, Edwards L. NK cells restrain CD8 T cells during tolerance
induction to islet allografts. XXII International Congress of The Transplantation Society
(Sydney, Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):255 (Abst. #731),
2008.
133.
Gill RG, Beilke J. A reappraisal of the passenger leukocyte model of islet allograft
immunogeneicity. XXII International Congress of The Transplantation Society (Sydney,
Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):448 (Abst. #1330), 2008.
134.
Ramirez-Victorino F, Beilke J, Gill RG. Host MHC class I-dependent immunity impairs
islet xenograft prolongation. XXII International Congress of The Transplantation Society
(Sydney, Australia, August 10-14, 2008). Transplantation 86(Suppl 2S):283 (Abst. #813),
2008.
135.
Wang S, Du L, Gill RG. LFA-1 perturbation and transplantation tolerance. Alberta
Diabetes Institute Research Day (September 26, 2008, Edmonton, AB). Abstract Book, pg.
17, 2008.
Updated: January 16, 2011
Ronald G. GILL
Page 26
136.
Thangavelu G, Gill RG, Anderson CC. Bystander killing of islet cells in an islet
transplantation model. Alberta Diabetes Institute Research Day (September 26, 2008,
Edmonton, AB). Abstract Book, pg. 32, 2008.
137.
Coulombe, M, Toews C, D Mann, L Yu, GS Eisenbarth, RG Gill. Mixed chimerism with
MHC-matched, disease resistant bone marrow results in dominant protection from diabetes
but not latent disease in NOD mice. 69th Scientific Sessions of the American Diabetes
Association (New Orleans, Jun 5-9, 2009). Diabetes 58(Suppl 1):A50, 2009
138.
Sklavos, MM, Bertera S, M Coulombe, R Gill, J Crapo, JD Piganelli. Redox modulation
protects islets from transplant-induced injury. 69th Scientific Sessions of the American
Diabetes Association (New Orleans, Jun 5-9, 2009). Diabetes 58(Suppl 1):A51, 2009
139.
Arefanian, H, Q Ramji, RV Rajotte, RG Gill, GS Korbutt, J Rodriguez-Barbosa, GR Rayat.
PD-1/PD-1L pathway is required for the induction and maintenance of tolerance to neonatal
porcine islet xenografts by combined anti-LFA-1 and anti-CD154 monoclonal antibodies.
Joint meeting of the International Pancreas and Islet Transplant Association / International
Xenotransplantation Association (Venice, Italy, Oct 12-16, 2009). Xenotransplantation
16:326, 2009.
140.
Arefanian, H, Q Ramji, RV Rajotte, RG Gill, GS Korbutt, GR Rayat. Combination of antiLFA-1 and anti-CD154 monoclonal antibodies induces dominant and CD4+ T cell dependent
tolerance to neonatal porcine islet xenografts. Joint meeting of the International Pancreas
and Islet Transplant Association / International Xenotransplantation Association (Venice,
Italy, Oct 12-16, 2009). Xenotransplantation 16:328-329, 2009
141.
Gill, RG, M Coulombe, C Toews, L Yu, GS Eisenbarth. Mixed chimerism with MHCmatched bone marrow transplantation results in dominant protection from autoimmune
diabetes. 97th Annual Meeting of the American Association of Immunologists, May 7-11,
2010, Baltimore, MD
142.
Arefanian, H., DC Mok, Q Ramji, PW Thompson, C Larsen, RG Gill, GS Korbutt, RV
Rajotte, GR Rayat. Immunogencity of islets isolated from three and seven day-old newborn
pigs. Transplantation 90(2S):313, 2010. XXIII International Congress of the
Transplantation Society, August 16, 2010, Vancouver, Canada
143.
Gill, RG, MR Nicolls, A Koh, M Coulombe. Impact of metabolic demand on islet transplant
survival and tolerance induction. Transplantation 90(2S):318, 2010. XXIII International
Congress of the Transplantation Society, August 16, 2010, Vancouver, Canada
Updated: January 16, 2011
Ronald G. GILL
Page 27
INVITED SPEAKER / MEETING PRESENTATIONS
2010
Invited Speaker: ‘Islet transplantation in the setting of autoimmunity’. Immunology Seminar Series,
University of Alabama, Birmingham. December 9, 2010
Invited Speaker: ‘Strategies and challenges for tolerance induction’. University of Wisconsin Transplant
Grand Rounds. University of Wisconsin, Madison. November 29, 2010.
Invited Speaker: ‘Strategies and pitfalls for inducing transplant tolerance.’ Plenary Session, 11th
Immunology of Diabetes Society Congress, November 3, 2010, Incheon, Korea
Guest Faculty: ‘Linking our understanding of innate and adaptive immunity in transplantation’.
American Society of Transplantation, Annual Scientific Exchange, October 21-24, 2010, Orlando, FL
Invited Speaker: ‘Relevance of autoimmunity islet transplantation’. Harvard Medical School / JDRF
Center. October 19, 2010. Boston, MA
Invited Speaker: ‘The split personality of pro-inflammatory immunity in transplantation’. Colorado
Clinical Scholars Program, September 11, 2010, Aspen, CO
Invited Speaker: ‘Pancreatic islet cell transplantation: have we forgotten about diabetes?’ Colorado
Clinical Scholars Program, September 12, 2010, Aspen, CO
Invited Speaker: State of the Art Lecture: ‘Significance of autoimmunity in clinical islet transplantation’
XXIII International Congress of the Transplantation Society, August 16, 2010, Vancouver, Canada
Guest Faculty/Lecturer: ‘Effector cells and injury mechanisms in transplantation’. Post-Graduate
Weekend Program, XXII International Congress of the Transplantation Society, August 16, 2010,
Vancouver, Canada
Guest Faculty/Lecturer: ‘Beyond T cell suppression’ American Society of Transplantation Fellows
Symposium; Basic Science Track. August 8, 2010, Grapevine, TX
Guest Faculty/Lecturer: ‘How is tolerance induced in the graft?’ American Society of Transplantation
Fellows Symposium; Basic Science Track. August 8, 2010, Grapevine, TX
Invited Speaker: ‘Immunology of Diabetes: Cliff notes for clinicians’. Management of Diabetes in
Youth Conference, July 17, 2010, Keystone, CO
Invited Speaker/Moderator: Grant Writing Workshop for Basic Scientists. American Transplant
Congress, May 4, 2010, San Diego, CA
2009
Need to update
2008
Invited Speaker: ‘Ying Yang of pro-inflammatory immunity in transplantation’. Canadian Society of
Transplantation Annual Scientific Meeting, Plenary Session 4. March 1, 2008, Mont-Tremblant,
Quebec.
Updated: January 16, 2011
Ronald G. GILL
Page 28
Invited Speaker: ‘Beta cell replacement in diabetes: successes and challenges’. J.B. Collip Club,
Faculty of Medicine & Dentistry, University of Alberta. March 4, 2008, Edmonton, AB.
Invited Speaker: ‘Immune dysregulation in autoimmune diabetes’. Montreal Diabetes Research Center
Seminar Series. March 12, 2008, Montreal, Quebec.
Invited Speaker: ‘Immunology of transplantation’. NSRRC Swine in Biomedical Research Conference.
April 3, 2008, San Diego, CA.
Invited Speaker: ‘T cell effector functions in acute rejection’. American Association of Immunologists
Experimental Biology 2008. April 5, 2008, San Diego, CA.
Invited Speaker: ‘The varied faces of natural killer cells in transplantation – contributions to both
allograft immunity and tolerance’. ISHLT 28th Annual Meeting and Scientific Sessions, Satellite
Symposium 4: Innate Immunity and Transplant Rejection. April 9, 2008, Boston, MA.
Invited Speaker: ‘Immune dysregulation in NOD mice’. Muttart Diabetes Research & Training Centre,
University of Alberta, April 14, 2008, Edmonton, AB.
Invited Speaker: ‘NK cells and immunomodulation in solid organ transplantation’. VII Congresso
Lusobrasileiro de Transplantacao. October 2, 2008, Albufeira, Portugal.
Invited Speaker: ‘The role of cellular cytotoxicity in transplant tolerance and rejection’. Immunology
Network Seminar, University of Alberta, October 23, 2008, Edmonton, AB.
Invited Speaker: ‘Immunobiology of islet transplantation’. 4th Canadian Beta Cell Working Group,
Montreal Diabetes Research Center, November 15, 2008, Montreal, Quebec.
2007
Invited Speaker: ‘The paradoxical role of pro-inflammatory immunity in allograft tolerance’. Keynote
Lecture, Great Lakes Transplant Immunology Forum. Emory University, January 19, 2007, Atlanta, GA.
Invited Speaker: ‘NK cell involvement in transplantation tolerance’. Plenary Lecture, 20th Annual
Spring Meeting of the Canadian Society for Immunology. March 17, 2007, Lake Louise, AB.
Invited Speaker: Early Morning Workshop #23 “Innate Immune Mechanisms” – Innate immunity in
allograft tolerance. 2007 American Transplant Congress. May 9, 2007, San Francisco, CA.
Invited Speaker: ‘Barriers for immune system evasion: what are we trying to accomplish?’
Biomaterials: Biocompatibility/Tissue Engineering, Gordon Research Conference. July 26, 2007,
Holderness, NH.
Invited Speaker: ‘Immunity to pancreatic islet allografts’. CTS, IPITA, IXA 2007 Joint Conference.
September 17, 2007, Minneapolis, MN.
Session Chair: “Early Bird Workshop 3: Tailored Immunosuppression.” CTS, IPITA, IXA 2007 Joint
Conference. September 18, 2007, Minneapolis, MN.
Session Chair: (C. Mathieu / R.G. Gill): “IPITA 3: ‘Control of Autoimmunity in Pancreas and Islet
Transplantation.’ CTS, IPITA, IXA 2007 Joint Conference. September 18, 2007, Minneapolis, MN.
Updated: January 16, 2011
Ronald G. GILL
Page 29
Invited Speaker: ‘The paradox of pro-inflammatory immunity in transplantation tolerance’. Transplant
Grand Rounds. “Visiting Professor in Transplantation”, University of California, San Diego. San Diego,
California. November 6, 2007.
Invited Speaker: ‘Clinical Islet Transplantation: a work in progress’. Visiting Professor in
Transplantation, University of California, San Diego. San Diego, California. November 6, 2007.
Invited Speaker: ‘Post Edmonton - Where do we go from here?’ Transplant Immunology Seminar
Series. Sponsored by the Children's Hospital of Philadelphia in conjunction with the University of
Pennsylvania School of Medicine, Philadelphia, PA. December 19, 2007.
2006
Invited Speaker : ‘Animal Models to Study Islet Transplantation’. Plenary Lecture, Rachmiel Levine
Diabetes and Obesity Symposium. Long Beach, CA. November 10, 2006.
Invited Speaker: ‘Expression and Regulation of Islet Allograft Immunity’. Transplantation Grand
Rounds. Thomas E. Starzl Transplantation Institute, University of Pittsburgh. Pittsburgh, PA.
September 29, 2006.
Invited Speaker: ‘Expression and Regulation of MHC Class I-Dependent Allograft Immunity’. Harvard
Medical School, Transplantation Center. Boston, MA. September 22, 2006.
Invited Speaker: ‘Allo versus Autoimmunity in Islet Transplantation’. Symposium Lecture, World
Transplant Congress. Boston, MA. July 24, 2006.
Invited Speaker: ‘Regulation of Graft-Reactive CD8 T-Cells in Allograft Tolerance’. Symposium
Lecture. 6th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS). San
Francisco, CA. June 3, 2006
Invited Speaker: ‘Role of NK cells in allograft tolerance induction’. NIH / JDRF Workshop on the Role
of Innate Immunity in Type I Diabetes. Denver, CO March 21, 2006.
2005
Invited Speaker: ‘Recognition pathways in islet transplant immunity’. Institute for Cellular
Therapeutics, University of Kentucky. Louisville, KY. Oct. 18, 2005.
Invited Speaker: ‘Islet allograft immunity: defining the rules of engagement’ Dept. Immunology
Retreat, Univ. Colo. Hlth. Sci. Center. Estes Park, CO. Sept. 22, 2005.
Invited Speaker: NOD mice: a model of exuberant indirect allograft immunity. Alberta Diabetes
Institute Retreat, University of Alberta. Edmonton, Alberta. Sept. 16, 2005.
Invited Speaker: ‘Prospects and Challenges of Analyzing Transplantation Immunity in Humanized
Mouse Models’. NIAID Biodefense Workshop on Humanized Mice. Bethesda Maryland. June 13-14,
2005.
Invited Speaker: ‘Effector pathways of T cell mediated injury of islet allografts’. American Association
of Immunologists (AAI) meeting, American Society of Transplantation Symposium Lecture. San Diego,
CA. April 4, 2005.
Updated: January 16, 2011
Ronald G. GILL
Page 30
2004
Invited Speaker: ‘MHC class I directed reactivity in islet allograft immunity and tolerance’. SurgicalMedical Research Institute. University of Alberta, Edmonton, Canada. Nov. 8, 2004.
Invited Speaker: ‘Islet Xenotransplantation’. Plenary Lecture, 5th Annual Rachmiel Levine Diabetes and
Obesity Symposium. Los Angeles, CA. October 6-9, 2004.
Invited Speaker: ‘T cell mediated allograft immunity and tolerance’. University of Colorado Health
Sciences Center / The Children’s Hospital Hypoplastic Left Heart Syndrome: A Fresh Look. Aspen, CO
August 6-8, 2004.
Invited Speaker: ‘The Encapsulated Islet in the Immune Environment’. NIH/JDRF sponsored
Symposium: Immunobarriers for Pancreatic Islet Transplantation, Washington D.C., March 29-30, 2004.
2003
Invited Speaker: ‘Islet Allograft Immunity and Tolerance’. Transplant Grand Rounds, University of
Michigan, Ann Arbor, Michigan. May 23, 2003.
Invited Speaker: ‘Islet Xenotransplantation: Prospects & Barriers’. Joslin Diabetes Center 2003
Symposium. Evading Beta Cell Death in Diabetes: Prevention and Transplantation. Boston, MA. May
4-6, 2003.
Invited Speaker: JDRF Research Update: ‘Status of Islet Transplantation’. JDRF Southwest Chapter.
New Mexico Health Sciences Center. Albuquerque, NM, April 22, 2003.
2002
Invited Speaker: ‘Islet Transplantation, Stem Cells, or Gene Therapy for a Cure’ 14th Annual Diabetes
Symposium. Memorial Hospitals Association. Modesto, CA. November 2, 2002.
Invited Speaker: ‘Allo vs Xeno Tolerance’. Symposium Lecture for the 62nd Scientific Sessions of the
American Diabetes Association. San Francisco, CA. June 17, 2002.
Invited Speaker: ‘Antigen Presentation Pathways’. Guest Faculty Lecture for Tissue Engineering PostGraduate Short Course: Biologically-Based Materials for Tissue Engineering. Georgia Institute of
Technology. Atlanta, Georgia. March 12, 2002.
2001
Invited Speaker: ‘Cellular Immunity to Immunoisolated Islet Grafts’. NASA/NIDDK/JDRF/NCRR
Workshop on Encapsulation & Immunoprotective Strategies of Islet Cells. Washington, DC, December
6-7, 2001. (Also advisor for NIH RFA development for islet encapsulation)
Invited Speaker: ‘Tribute to Kevin J. Lafferty’. Introductory Lecture to the 10th Anniversary Congress,
Cell Transplant Society. Keystone, CO. October 14, 2001.
Invited Speaker: ‘Rejection vs. recurrent autoimmunity in pancreas and islet transplantation’. Plenary
Lecture at the 8th Congress of the International Pancreas and Islet Transplant Association. Innsbruck,
Austria. June 15, 2001.
Invited Speaker: ‘Clinical Pancreatic Islet Transplantation’. UNOS Region 8 Clinical Transplant Forum.
Denver, CO. April 26, 2001.
Updated: January 16, 2011
Ronald G. GILL
Page 31
Invited Speaker: ‘Allograft Tolerance’. Medical College of Georgia. Augusta, GA. March 13, 2001.
Invited Speaker: ‘Human islet cell transplantation’. Controversies in Transplantation. Breckenridge,
CO. March 9, 2001.
Invited Speaker: ‘Diabetes research update: pancreatic islet transplantation’. Juvenile Diabetes Research
Foundation & Humphreys Diabetes Education Center. Boise, Idaho. February 21, 2001.
2000
Invited Speaker: ‘Pathways of T cell recognition of islet transplants’. Scripps Research Institute. La
Jolla, CA. December 5, 2000.
Invited Speaker: ‘Analysis of immunoisolation technology with small animal models’. Artificial Organs
III, United Engineering Foundation. Davos, Switzerland. October 10, 2000.
Invited Speaker: ‘Mechanisms of islet allograft and xenograft immunity’. Plenary lecture of EASD
satellite meeting: Combined islet basic science & transplantation meeting. Eilat, Israel. September 24,
2000.
Invited Speaker: ‘Basis of immunogenicity for endocrine allografts’. 10th International Symposium on
Immunobiology of Proteins and Peptides. Tahoe City, California. September 14, 2000.
Invited Speaker: JDF Research Update: Islet Transplantation, Juvenile Diabetes Foundation, Las Vegas
Chapter. Las Vegas, NV. June, 29, 2000.
Invited Speaker: ‘Cellular immune response to islet transplants’. Mayo Clinic, Rochester, MN. June 5,
2000.
Invited Speaker: ‘Mechanisms of allo- and xeno-islet cell destruction’. Basic Science Symposium
Lecture. . 1st Joint Meeting of the American Society of Transplantation. . 1st Joint Meeting of the
American Society of Transplantation. Chicago, IL. May 16, 2000.
Invited Speaker: JDFI: Insulin dependent diabetes research update. JDFI Rocky Mountain Chapter.
Denver, CO . April 29, 2000.
1999
Invited Speaker: ‘Paradoxes of pancreatic islet allograft immunity and tolerance’ University of Alberta.
Edmonton, Canada. September 17, 1999.
Invited Speaker: ‘Tolerance will work’. Plenary lecture of the International Pancreas and Islet
Transplant Society. Sydney, Australia. August 22, 1999.
Invited Speaker: ‘Cellular Immunity and Tolerance to Islet Allografts’. Keystone Symposium,
Molecular and Cellular Biology of Transplantation. Lake Tahoe, Nevada, March 21-26, 1999.
1998
Invited Speaker: ‘Transplantation Tolerance’. Anergen, Inc. Redwood City, CA. August 31, 1998
Invited Speaker: ‘Antigen presentation pathways in allograft and xenograft rejection’. Bioartificial
Organs II: Technology, Medicine, and Materials. Engineering Foundation, Canmore, Alberta, Canada,
July 18-22, 1998.
Updated: January 16, 2011
Ronald G. GILL
Page 32
Invited Speaker: ‘Tolerance to pancreatic islet allografts’. University of Wisconsin-Madison Medical
School. Madison, Wisconsin. May 5, 1998.
Invited Speaker: ‘ Pathogenesis of autoimmune diabetes’. University of Wisconsin-Madison Medical
School. Madison, Wisconsin. May 4, 1998.
Invited Speaker: ‘Islet Transplantation in Autoimmune Diabetes’. Longwood Area
Diabetes/Metabolism Research Seminar Series. Joslin Diabetes Center. Boston, Massachusetts. March
5, 1998.
Invited Speaker: ‘Immunology of Islet Transplantation’. Mini-symposium: Targets of opportunity for
treatment and prevention of insulin-dependent diabetes mellitus (IDDM). Boehringer Ingelhein.
Ridgefield, Connecticut, January 15, 1998.
1997
Invited Speaker: ‘Human and Animal Islet Transplantation’. Strategic Planning Workshop on Beta-Cell
Replacement. Juvenile Diabetes Foundation International & National Aeronautics and Space
Administration. Washington, D.C. December 2-3, 1997.
Invited Speaker: ‘Rejection of pancreatic islet allografts mediated by CD8+ T cells’.
Cleveland Ohio. September 5, 1997.
Cleveland Clinic,
Invited Speaker: JDFI Research Update, Juvenile Diabetes Foundation International, Kansas City
Chapter. Kansas City, MO. June 12, 1997.
Invited Speaker: ‘Immunobiology of islet graft rejection’. Symposium lecture, 16th Annual Meeting of
the American Society of Transplant Physicians. Chicago, IL. May 13, 1997.
Invited Speaker: ‘T lymphocyte-dependent pathogenesis in islet transplantation ‘. University of Alberta,
Department of Surgery. Edmonton, Alberta, Canada. March 17, 1997.
1996
Invited Speaker: ‘Tolerance does not require clonal deletion of antigen-specific T cells’. 15th Plenary
Session, Immunology of Diabetes Workshop. Canberra, Australia. December 9, 1996.
Invited Speaker: ‘The role of CD4 T cells in pancreatic islet transplantation immunity’. SmithKline
Beecham Pharmaceuticals sponsored Transplantation Symposium. Collegeville, Pennsylvania. May 7,
1996.
Invited Speaker: ‘T cell-dependent pathogenesis in pancreatic islet transplantation’. Alberta Heritage
Foundation for Medical Research, University of Alberta, Edmonton, Canada. March 27, 1996.
Invited Speaker: ‘T Cell-Dependent Damage in Pancreatic Islet Transplants’. University of Maryland
Medical Center Transplantation Program. Baltimore, Maryland. February 14, 1996.
1995
Invited Speaker: ‘Transplantation Immunity and Tolerance: The Two-Signal Hypothesis Revisited’.
Ohio State University College of Medicine Immunology Seminar. The Ohio State University. Columbus,
Ohio. November 7, 1995.
Invited Speaker: ‘Immunobiology of Islet Transplantation’. University of Kansas Medical Center.
Kansas City, Missouri. October 26, 1995.
Updated: January 16, 2011
Ronald G. GILL
Page 33
Invited Speaker: ‘Pathogenesis of Autoimmune Diabetes’. University of Kansas Medical Center.
Kansas City, Missouri. October 25, 1995.
Invited Speaker: ‘Role of Cytokines in Tolerance and Rejection’. Plenary Lecture, Symposium on
Tolerance: From Bench to Bedside. Boston, Massachusetts. September 26, 1995.
Invited Speaker: ‘Immune Cellular Effectors/Regulation’. Immune Mechanisms of Cardiovascular
Disease. Aspen, Colorado. August 10-12, 1995.
Invited Speaker: ‘The Immunobiology of Islet Transplantation’. Plenary Session of the Fifth Congress
of the International Pancreas and Islet Transplantation Association. Miami, Florida. June 22, 1995.
Invited Speaker: ‘The Basis of Tissue Immunogenicity’. University of Minnesota, Dept. of Surgery
Transplant Conference. March 2, 1995.
1994
Invited Speaker: ‘Update on Transplantation’. Plenary Session, Management of Pediatric Diabetes,
Keystone, Colorado. August 3, 1994.
Invited Speaker: ‘Immunobiology of Cellular Transplantation’. Plenary Session, 2nd International
Congress of the Cell Transplantation Society. Minneapolis, Minnesota. May 3, 1994.
1993
Invited Speaker: ‘Pancreatic Islet Xenografting’. Muttart Diabetes Research and Training Centre/
Surgical-Medical Research Institute, University of Alberta, Edmonton, Canada. September 21, 1993.
Invited Speaker: ‘Pancreatic Islet Xenografting’. Diacrin, Inc. Charlestown, Maryland. September 5,
1993.
Invited Speaker: ‘Immunobiology of Pancreatic Islet Xenografting’. Baxter Healthcare Corporation.
Chicago, Illinois. May 19, 1993.
Invited Speaker: ‘Islet Cell Xenografting’. Plenary Session of the 12th International Immunology and
Diabetes Workshop. Orlando, Florida. April 18, 1993.
Invited Speaker: ‘Lack of peripheral (extrathymic) tolerance induction to pancreatic islet allografts’.
Denver Immunology Research Symposium. Denver, Colorado. April 3, 1993.
1992
Invited Speaker: ‘T-T lymphocyte collaboration in islet allograft rejection’. Muttart Diabetes Research
and Training Centre/ Surgical-Medical Research Institute, University of Alberta, Edmonton, Canada.
April 24, 1992.
1991
Invited Speaker: ‘The role of T lymphocyte subsets in islet graft immunity’. University of Minnesota,
Dept. of Surgery Transplant Conference. December 12, 1991.
Invited Speaker: ‘Islet transplantation in Type I Diabetes’. Plenary Session, American Association of
Tissue Banks 15th Annual Meeting. Clearwater Beach, Florida. September 30, 1991.
Updated: January 16, 2011
Ronald G. GILL
Page 34
Invited Speaker: ‘T-T collaboration in islet allograft immunity’. DNAX Research Institute of Molecular
and Cellular Biology, Inc. Palo Alto, California. February 20, 1991.
Invited Speaker: ‘Role of passenger leukocytes in islet allograft rejection’. Plenary Session,
Breckenridge Symposium on Tolerance Induction: Breckenridge, Colorado. January 15-18, 1991.
1990 and prior
Invited Speaker: ‘The role of T cell help in pancreatic islet allograft rejection’. University of Florida
College of Medicine, Dept. of Pathology, Gainesville, Florida. September 19, 1990.
Invited Speaker: ‘Islet transplantation in Type I diabetes mellitus ‘. Cellular Transplants, Inc.
Providence, Rhode Island, March 8, 1990.
Invited Speaker: ‘Role of passenger leukocytes in islet allograft immunity’. Plenary Session of the 2nd
International Congress on Pancreatic and Islet Transplantation, Minneapolis, Minnesota, September 22,
1989.
Invited Speaker: ‘Islet cell implantation for diabetes’. Cell Implantation Workshop (Miles
Pharmaceuticals). Berkeley, California January 27, 1988.
Invited Speaker: ‘Islet cell transplantation’. Colorado Transplant Symposium. Denver, Colorado, April
14, 1988.
Invited Speaker: ‘Spontaneous animal models of diabetes mellitus: Transplantation in diabetic animals’.
(BB and NOD) 38th Annual meeting: American Association of Laboratory Animal Science; Denver,
Colorado; November 12, 1987.
Updated: January 16, 2011
Ronald G. GILL
Page 35
CONTRACT RESEARCH FUNDING - CURRENT
o
Geron Corporation
Title: Characterization and differentiation of human embryonic stem cells into functional
pancreatic islets.
Principal Investigator: Dr. G. Korbutt (Co-PI) / Dr. R. Gill (Co-PI)
Entire Project Period: July 1/08 to June 30/09
Amount: $208,701.00 US
Updated: January 16, 2011
Ronald G. GILL
Page 36
GRANT FUNDING - CURRENT
o
Juvenile Diabetes Research Foundation (JDRF 5-2010-628)
Type: Innovative Research
Title: CD117+ Stem Cells for Facilitating Islet Transplantation
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 09/01/2010-08/31/2011
Year 1 = $100,000 US
o
Juvenile Diabetes Research Foundation (JDRF #4-2008-812)
Type: Center Grant
Title: Project 2 – The interplay between metabolic stress and immune activation in islet
transplantation.
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 07/01/2008-06/30/2011
Year 1 = $126,022 US
o
Juvenile Diabetes Research Foundation (JDRF #4-2008-812)
Type: Center Grant
Title: Co-Director – Islet Protection, Regeneration and New Sites for Implantation.
Co-Directors: A.M.J. Shapiro, MD and Ronald G. Gill, PhD
Entire Project Period: 07/01/2008-06/30/2011
Year 1 = $599,754 US
Year 2 = $580,657 US
Year 3 = $546,969 US
o
Alberta Heritage Foundation for Medical Research (AHFMR) 200700786
Type: Scientist
Title: The role of natural killer (NK) cells in transplantation tolerance
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 07/01/2008-06/30/2015
Establishment Grant: $400,000 total amount (start 07/01/2008 – end 06/30/2010)
Research Allowance: $350,000 total amount (start 07/01/2008 – end 06/30/2015)
Research Prize: $140,000 total amount (start 07/01/2008 – end 06/30/2015)
Equipment Amount: $100,000 total amount (start 07/01/2008 – end 06/30/2009)
o
Canadian Institutes of Health Research (CIHR 200806RMF-189940-RMC-CBAA-101858)
Type: Emerging Team Grant: Regenerative Medicine and Nanomedicine
Title: Nanomedicine in organ transplantation: polysaccharide structures as immunologic
tolerogens for infant heart transplantation.
Principal Investigator: Dr. Lori J. West
Role on Project: Ronald G. Gill, PhD, et al. (co-investigators)
Entire Project Period: 10//01/2008-09/30/2013
Funding: $404,214 / year
Updated: January 16, 2011
Ronald G. GILL
Page 37
GRANT FUNDING - PAST
o
NIH/NIAID 1 U19 AI46374-05 (Kotzin)
5% effort
Title: Denver Autoimmunity Center of Excellence
Principal Investigator: Brian Kotzin MD
Entire Project Period: 09/30/03-03/31/08
Role on Project: Co-investigator Basic Project 2 (Holers)
Complement in the Immunopathogenesis of Autoimmune DiabetesAnnual Direct Costs (Project 2): $150,000
Project Description : The major goals of this project are to determine the contribution of
complement receptors CR2 and CR1 to the development of  cell injury and diabetes in NOD
mice, and to determine the ability of complement inhibitors targeted at C3 activation steps to
block the development of  cell injury and diabetes in NOD mice.
o
NIH RO1 DK33470
15% effort
Title: Reversal of Diabetes by Islet Transplantation
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 4/01/84 - 1/31/07
Annual Direct Costs: $184,500
Project Description: The objective of this proposal is to determine the mechanism of tolerance to
pancreatic islet allografts: (1) Determine whether tolerance is dominant or recessive, (2)
Determine the requirements for tolerance induction, and (3) Determine the fate of relevant ,
graft-reactive T cells within a tolerizing environment.
o
Source: NIH RO1 DK45773
15% effort
Title: Immunobiology or Pancreatic Islet Xenografting
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 1/1/93- 12/31/06
Annual Direct Costs: $132,000
Project Description: The objective of this proposal is to determine the nature of cellular
immunity to pancreatic islet xenografts by determining: (1) The basis of cellular rejection
triggered by CD4 T cells, and (2) The basis of altered cellular reactivity resulting in long-term
xenograft acceptance following anti-LFA-1 (CD11a) therapy.
o
Source: NIH RR16599-01
25% effort
Title: Islet Cell Resources (ICR) Facility at the University of Colorado Health Sciences Center
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 9/30/01-8/31/06
Annual Direct Costs: $755,000
Project Description : Develop and improve methods of islet harvesting and isolation.
Program Official: Richard Knacek
Phone: 301-435-0792
E-mail: richardk@ncrr.nih.gov
Updated: January 16, 2011
Ronald G. GILL
Page 38
o
Source: NIH R01 HL67976-01
10% effort
Title: The mechanism of CD40 T cell dependent acute cardiac allograft rejection
Principal Investigator: Biagio A. Pietra
Role on Project: Co-Investigator
Entire Project Period: 7/1/01 - 6/30/06
Annual Direct Costs: $225,000
Project Description: To clarify the role of CD4 T cells in acute cardiac allograft rejection.
Program Official: David Lathrop
Phone: 301-435-0504
E-mail lathrop@nih.gov
o
Source: NIH DK/AI 55333
15% effort
Title: T cell-mediated injury to islet allografts
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 9/30/02 - 9/29/05
Annual Direct Costs: $143,568
Project Description : The objective of this proposal is to determine the relative effector of
mechanisms of CD8-mediated islet allograft immunity and CD4-mediated autoimmune islet
injury.
o
Source: JDRF 1-2002-127
5% effort
Title: Pre-clinical approaches to islet allograft tolerance
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 9/1/02 - 8/31/05
Annual Direct Costs: $123,847
Project Description : The objective of this proposal is to determine the relative capacity of
autoimmune-prone NOD mice to pancreatic islet allografts.
o
Source: NIH DK57516
5% effort
Title: Diabetes and Endocrinology Research Center
Principal Investigator: John Hutton, PhD
Role on Project: Director, Animal Core
Entire Project Period: 6/1/00-3/31/05
Annual Direct Costs: $675,051
Project Description : DERC grant supporting core laboratories.
Program Official: Thomas L. Eggerman
Phone: 301-594-8813
E-mail eggermant@extra.niddk.nih.gov
o
Source: NIH R21 AI 060349-01
10% effort
Title: Use of hematopoietic stem cells for the regulation of autoimmune diabetes
Principal investigator: Ronald G. Gill, PhD
Entire Project Period: 9/30/03 – 8/31/05
Annual Direct Costs: $150,000
Project Description : The goal of this project is to use MHC-matched bone marrow allografts to
restore autoimmune propensity and to restore peripheral allograft tolerance defects in
autoimmune-prone NOD mice.
Updated: January 16, 2011
Ronald G. GILL
Page 39
o
Source: Juvenile Diabetes Foundation
5% effort
Title: Manipulation of complement activities as a novel therapeutic strategy for autoimmune
IDDM
Principal Investigator: V. Michael Holers, MD
Role on Project: Co-investigator
Entire Project Period: 7/1/99 - 6/30/01
Annual Direct Costs: $90,900
Project Description : The objective of this proposal is to determine the contribution of
complement components and receptors in the pathogenesis of autoimmune diabetes.
o
Source: Juvenile Diabetes Foundation
10% effort
Title: T lymphocyte-dependent immunity to encapsulated islet allografts
Principal Investigator: Ronald G. Gill, PhD
Entire Project Period: 9/1/99 - 8/31/01
Annual Direct Costs: $90,909
Project Description : The objective of this proposal is to understand the nature of T lymphocytedependent immunity to encapsulated pancreatic islet allografts.
o
Source: Juvenile Diabetes Foundation
Identifying number: #194133
Title: Autoimmune pathogenesis in islet transplants
Period of Support: 9/1/94-8/31/96
Annual Direct Costs: $45,031
Role on Project: Principal Investigator
o
Source: Juvenile Diabetes Foundation
10% effort
Identifying number: #195031
Title: Protection from autoimmune-mediated islet injury through gene therapy
Period of Support: 9/1/95-8/31/97
Annual Direct Costs: $45,345
Role on Project: Principal Investigator
o
Source: Baxter Healthcare Corporation
5% effort
Title: Autoimmune triggering and regulation by immunoisolated islet antigens
Period of Support: 7/13/96 - 7/12/97
Role on Project: Principal Investigator
Annual Direct Costs: $19,073
o
Source: Juvenile Diabetes Foundation
90% effort
Identifying number:#291292
Title: Mechanisms of pancreatic islet allograft and xenograft rejection
Proposed Period of Support: 7/1/91-6/30/94
Annual Direct Costs: $45,000
Role on Project: Principal Investigator (Career Development Award)
o
Source: Juvenile Diabetes Foundation
15% effort
Identifying number: #190995
Title: The role of lymphocyte subsets in pancreatic islet graft rejection
Period of Support: 9/90-8/92
Annual Direct Costs: $49,286
Role on Project: Principal Investigator
Updated: January 16, 2011
10% effort
Ronald G. GILL
o
Source: Juvenile Diabetes Foundation
100% effort
Identifying number: #388180
Title: Mechanisms of T-T lymphocyte collaboration in islet allograft immunity.
Period of Support: 7/88-6/90
Annual Direct Costs: $27,000
Role on Project: Principal Investigator (fellowship)
o
Source: Juvenile Diabetes Foundation
10% effort
Identifying number:#18881
Title: Mechanisms of T-T lymphocyte collaboration in islet allograft immunity.
Period of Support: 9/88-8/90
Annual Direct Costs: $42,361
Principal Investigator: Kevin J. Lafferty
Role on project: co-investigator
Updated: January 16, 2011
Page 40
Ronald G. GILL
Page 41
TEACHING
1) COURSES / LECTURES
Current
Graduate Courses (University of Alberta)
o Course: Surgery 520, University of Alberta; Transplantation Immunology Allograft, 2008/2009
school year (January 29/09)
Lectures: 1 hour lecture
o Course: Surgery 520, University of Alberta; Transplantation Immunology Xenograft, 2008/2009
school year (February 5/09)
Lectures: 1 hour lecture
Past
Graduate Courses (University of Colorado Health Sciences Center)
o Course: MICB 7631; The Cell Biology of the Immune System, 1989-90
Lectures: 2 lecture hours on interleukins and cytokine receptors.
2 lecture hours on mechanisms of graft rejection.
o Course: MICB 7631; The Cell Biology of the Immune System, 1990
Lectures: 6 lecture hours on cytokines and cytokine receptors.
o Course: MICB 7631; The Cell Biology of the Immune System, Winter 1991-1992. Lectures: 6
lecture hours on cytokines and cytokine receptors.
o Course: IDPT 7663; Immune response to infectious agents and Immunopathology, Winter 19921993. Lectures: 6 lecture hours on cytokines and cytokine receptors.
o Course: IDPT 7664; Immune response to infectious agents and Immunopathology, Spring 1993.
Lecture: 2 lecture hours on graft-versus-host-disease.
o Course: IMMU 7663; Immune response to infectious agents and Immunopathology, Winter
1993-1994. Lectures: 6 lecture hours on cytokines and cytokine receptors.
o Course: IMMU 7664; Immune response to infectious agents and Immunopathology, Spring
1994. Lecture: 4 lecture hours on transplantation.
o Course: IMMU 7663; Cell Biology of the Immune System, Winter 1994-1995. Lectures: 6
lecture hours on cytokines and cytokine receptors.
o Course: IMMU 7664; Immune response to infectious agents and Immunopathology, Spring
1995. Lecture: 4 lecture hours on transplantation immunology.
o Course: IMMU 7663; Cell Biology of the Immune System, Winter 1995-1996.
Lectures: 6 lecture hours on cytokines and cytokine receptors.
o Course: IMMU 7664; Immune response to infectious agents and immunopathology, Spring
1996. Lecture: 4 lecture hours on transplantation.
o Course: IMMU 7663; Cell Biology of the Immune System, Winter 1996-1997.
Lectures: 6 lecture hours on cytokines and cytokine receptors.
o Immunology Program AMGEN Lecture Series; 2 Lecture hours on transplantation. Boulder,
CO. March 21, 1996.
o Course: IMMU 7663; Cell Biology of the Immune System, Winter 1997-1998.
Lectures: 6 lecture hours on cytokines and cytokine receptors.
Updated: January 16, 2011
Ronald G. GILL
o
o
o
o
o
o
o
o
o
o
o
Page 42
Course: IMMU 7664; 2 Lecture hours on animal models of transplantation, Spring 1998
Course: IMMU 7662; The Immune Response, Winter 1999-2000.
Lectures: 9 lecture hours on costimulation, cytokines, cytokine receptors, host responses to
pathogens
Course: IMMU 7663; Advanced Immunolog,y Spring 2000.
Lectures: 2 lecture hours on transplantation immunology
Course: IMMU 7663; Advanced Immunolog,y Spring 2000.
Lectures: 4 lecture hours on cytokine biology
Course: IMMU 7662; The Immune Response, Winter 2000-2001.
Lectures: 7 lecture hours on costimulation, cytokines, cytokine receptors, innate immunity
Course: IMMU 7662; The Immune Response, Winter 2001-2002.
Lectures: 9 lecture hours on costimulation, cytokines, cytokine receptors, innate immunity
Course: IMMU 7663; Advanced Immunolog,y Spring 2002.
Lectures: 12 lecture hours on costimulation, cytokines, cytokine receptors, antigen presenting
cells, transplantation immunology
Course: IMMU 7662; The Immune Response, Winter 2002-2003.
Lectures: 1 lecture hour on paradigms in immunology
Course: IMMU 7663; Advanced Immunology, Spring 2003.
Lectures: 16 lecture hours on costimulation, cytokines, cytokine receptors, antigen presenting
cells, transplantation immunology
Course: IMMU 7663; Advance Immunology, Spring 2004
Lectures: 12 lecture hours on costimulation, cytokines, antigen presenting cells, transplantation
Course: IMMU 7663; Advance Immunology, Spring 2005
Lectures: 14 lecture hours on costimulation, cytokines, antigen presenting cells, transplantation
Course Coordinator (University of Colorado Health Sciences Center)
o IMMU 7663; The Immune Response, Winter 1996-1997
o IMMU 7662; The Immune Response, Winter 1997-1999
o MMU 7662; The Immune Response, Winter 1999-2000
o IMMU 7662; The Immune Response, Winter 2000-2001
o IMMU 7662; The Immune Response, Winter 2001-2002
o IMMU 7662; The Immune Response, Winter 2002-2003
Department of Medicine Lectures (University of Colorado Health Sciences Center)
o UCHSC Transplantation Immunology Program. September, 1998
o Lectures: 4 hours of introductory lectures on transplantation immunology
o Transplantation Tolerance. Pulmonary Division Research in Progress. Sept 24, 1999
o Renal Physiology Course: Lecture on. Transplantation Immunology May 22, 2000
o Transplantation Immunology: The Year in Review UCHSC Association of Transplant Physicians
and Surgeons. September, 2000
o Clinical Islet Transplantation UCHSC Association of Transplant Physicians and Surgeons.
November, 2000
Updated: January 16, 2011
Ronald G. GILL
Page 43
2) GRADUATE STUDENT SUPERVISION
Current
Supervisor / Thesis Advisor
o Selena Wang, 2008-current (PhD, Medical Microbiology & Immunology)
o David Al-Adra, 2009-2010 (MSc, Experimental Surgery)
o Christian Toso (PhD Exam / Defense)
o William Chan (PhD Defense)
o Bryce Liang (MSc Defense)
o Angela Koh
o Troy Baldwin (mentor)
o Lillian Du, 2008 (summer student)
Thesis Advisor/Supervisor
o Marilyne Coulombe; 1990-1993 (awarded PhD 11/93) (Joint supervision with the University of
Alberta)
o Leslie Wolf; 1992-1995 (awarded PhD 2/96)
o Ricardo Araujo (University of Lisbon, Portugal MSTP Program); 1996-1997
o Megan Crawford, graduate student; 1993-1998 (awarded PhD 12/98)
o Andrew Diamond, graduate student (MSTP); 1995-2000 (awarded PhD 12/2000)
o Tinalyn Malecki; 1997-2003 (PhD awarded 11/2003)
o Zachary Johnson, graduate student; 1999-2004 (Masters awarded 2004)
o H. Carl Gelhaus, graduate student; 1999-2004 (PhD awarded 10/2004)
o Joshua Beilke, graduate student; 2002-2005 (PhD awarded 11/2005)
o Michelle Sleater, graduate student (MSTP); 2001-2006 (PhD awarded 3/2006)
o Jonathan Kurche (MSTP); 2005-2007
o Selena Wang, 2008-present, graduate student (University of Alberta)
o Adam Burrack, 2010-present, graduate student (University of Colorado)
Graduate Student Thesis Committee
o Peg Squier; 1993-1995
o Pamela Smith (Chair); 1994-1997
o Sherry Fleming; 1994-1996
o Michelle Poulin: 1994-2000
o Robert Kelly (Chair); 1998-2000
o Gina Rayat, University of Alberta – External Examiner
o Robert Shapiro; 1998-2002
o Kara Lukin; 1998-2004
o Joseph Cantor 1999-2005
o Eli Boritz; 2001-2004
o Jeffery Tessem-Sivert; 2003-present
o Kristine Kuhn – 2003-2005
o Amanda Kostyk; 2003-2006
o Sarah J. Lord, University of Alberta – External Examiner
o Brian Stadinski (Chair) – 2004 - present
Laboratory Rotation Supervisor
o Leslie Miller; 1991
o Dylan Daniel; 1992
o Meagan Scholl; 1993
Updated: January 16, 2011
Ronald G. GILL
o
o
o
o
o
o
o
o
o
o
o
o
o
Page 44
Karen Makar; 1994
Andrew Diamond; 1995
Nick Craig; 1996
Tinalyn Malecki; 1997
Zachary Johnson (BSP); 1999
Carl Gelhaus; 1999
Joseph Cantor; 1999
Michelle Sleater; 2001
Anatoly Rubtsov, 2002
Darlynn Korns, 2005
Lindsay Edwards, 2005
Jonathan Kurche, 2005
Jonathan Hill, 2006
Qualifying Examination Committees
o Tina Ellis, 1992
o Peg Taylor, 1992
o Angela Dallas, 1993
o Michael Princiotta, 1994
o Lisa Lehman, 1994
o David Poticha, 1994
o Karen Makar, 1995 (Chair)
o Mark Hertz, 1995 (Chair)
o Dan Fitzsimmons, 1996 (Chair)
o John Stolpa, 1996 (Chair)
o Robert Kelly, 1997 (Chair)
o Murry Wynes, 1997 (Chair)
o Juli Moticka, 1998 (Chair)
o Gary Shapiro, 1998 (Chair)
o Steven J. Kattman, 2000
o Joseph Cantor, 2000
o Dalya Roser, 2000
o Holly Maier, 2001
o Eli Bortiz, 2001
o Kristi Kuhn, 2002
o Daniel Tonkin, 2002
o Anatoly Rubtsov, 2003
o Raedun Clarke, 2003
o Kimberly Mace, 2004
o Jason Oh, 2006
o Corinne Depersis, 2006
3) FELLOWSHIP & FACULTY MENTORING
o
Mark Stegall, MD, Department of Surgery, UCHSC. Scientific mentor for Dr. Stegalls American
Diabetes Association Career Development Award. 1995-1998. Current position: Professor,
Director, Pancreas and Kidney Transplantation, Mayo Clinic, Rochester, MN.
o
Biago Pietra, MD, Department of Pediatrics, Division of Cardiology, Children’s Hospital,
Denver, CO. Scientific mentor for Dr. Peitras American Hearth Association grant (1995-1996),
Updated: January 16, 2011
Ronald G. GILL
Page 45
and NIH KO8 award (1997-2002). Co-investigator on Dr. Pietra’s NIH RO1 award (2003-2007)
Current Position: Professor of Pediatrics, Chief of Pediatric Cardiac Transplant Program, The
Children’s Hospital and University of Colorado.
o
Marilyne Coulombe, PhD Post-doctoral fellow supervisor: (1994-1999). Current Position:
Research Associate, University of Colorado Health Sciences Center
o
Huan Yang, MD, Regular fellow supervisor: (1994-1997)
o
Tul Kalayanamit, MD, Department of Medicine, Pulmonary Division, UCHSC. Scientific
Mentor (1996-1998)
o
Mark Nicolls, MD, Department of Medicine, Pulmonary Division, UCHSC (1997-2005).
Scientific sponsor for Dr. Nicolls NIH K08 award (2000-2005). Current Position: Professor
and Chief of Pulmonary Division, Stanford University.
o
Alex Wiseman, MD, Department of Medicine, Division of Nephrology, UCHSC (1997-2006).
Scientific sponsor for Dr. Wisemans NIH F32 award (1998-2001) and NIH K08 award (2001present). Currently: Associate Professor of Medicine, Chief of Kidney Transplant Program,
University of Colorado
o
Gina Rayat, PhD Post-doctoral fellow supervisor (1999-2002) Immunobiology of islet
xenotransplantation. Scientific sponsor for JDRF fellowship award Currently: Assistant
Professor of Surgery, University of Alberta
o
Todd Grazia, MD Assistant professor, Department of Medicine, Pulmonary Division, UCHSC
(2002 – present) Scientific sponsor for NIH NRSA fellowship award and NIH KO8 award
(2005-2009). Currently: Assistant Professor of Medicine, Pulmonary Division, University of
Colorado
o
Tinlyn Kupfer, PhD Post-doctoral fellow (2003 –present). Pathogenesis of autoimmune
diabetes. Scientific sponsor for ADA Mentored Fellowship Award.
o
Sarah Weber, PhD Post-doctoral fellow supervisor (2004-prsent). Regulation of islet transplant
rejection by regulatory T cells. Scientific sponsor for JDRF fellowship award.
o
Cara Mack, MD Assistant Professor, Department of Medicine. Pathogenesis of biliary atresia.
Scientific co-sponsor for NIH KO8 award. Current Position: Associate Professor of Medicine,
Gastroenterology Division, University of Colorado
Updated: January 16, 2011